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ABSTRACT
COMPARISON   BETWEEN  ANTIPROTEINURIC  EFFECTS  OF
CILNIDIPINE AND AMLODIPINE AS ADD ON THERAPY IN
HYPERTENSIVE   PATIENTS WITH CHRONIC RENAL DISEASES
AIM: To  compare  the  efficacy  and  safety  of  cilnidipine  and  amlodipine as
add  on  therapy  in  chronic  kidney  disease  patients  who  are  on  losartan
(Angiotensin  receptor  blocker) for     > 2  months.
METHODS: In  this  prospective, single  centered, open  labeled, randomized
study, the  antiproteinuric  effects  of  cilnidipine (L/N  type  calcium  channel
blockrer) and  amlodipine (L  type  calcium  channel  blocker) were  examined  in
diabetic  chronic  renal  disease patients  with  hypertension   (BP ≥ 130/80
mmHg)  who  are  already  under  treatment  with  T. Losartan  50  mg  OD.
Antiproteinuric  effects  were  assessed  by  reduction  in  spot  urine  protein
creatinine  ratio  from  baseline.
RESULTS: Patients  received  cilnidipine (n=46)  or  amlodpine  (n=50)  for  6
months. Cilnidipine  and  amlodipine  reduced  systolic  and  diastolic  blood
pressure  equally. The  spot  urine  protein  creatinine  ratio  values  for  cilnidipine
and  amlodipine  were 1.94±1.22 g/g  and  1.38±0.98 g/g respectively before
treatment  and 1.09±0.72 g/g  and  1.40±0.65 g/g respectively  after  treatment. The
mean  serum  creatinine  concentration  gradually  increased  in  both   the  groups
and  attained  statistical significance  at  the  end  of  6  months. Estimated  GFR
was  maintained  by  both  the  drugs  throughout  the  study  period. Distribution
of  CKD stages  were  also  similar  between  the  two  groups  before  and  after
treatment. None  of  the produced  reflex  tachycardia.
CONCLUSION: In  conclusion,  cilnidipine  has  antihypertensive  effect
equivalent  to  amlodipine but addition  of  cilnidipine  rather  than  amlodipine
to  losartan  decreased urine  protein  excretion   in  diabetic chronic  kidney
disease  patients. Therefore  combination therapy  with  cilnidipine  and  RAS
inhibitor  may  be  more  beneficial  and  renoprotective  in  patients  with  diabetic
chronic  kidney  disease.
KEY  WORDS: L/N  type  calcium  channel  blocker, L type  calcium  channel
blocker, Angiotensin  receptor  blocker, Diabetic  chronic  kidney  disease/chronic
renal disease, Hypertension, Urine  protein  creatinine  ratio, antiproteinuric
effects.
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INTRODUCTION: 
                   Chronic  kidney  disease (CKD) comprises  of   a  spectrum  of 
different pathophysiological  processes  associated  with  abnormal  kidney  
function  and  progressive decline  in  glomerular  filtration  rate. Diabetic  
nephropathy  is  the   most  common  cause  of  chronic  renal  failure  
worldwide. It  is  mainly  due  to  epidemic  increase  in  obesity, metabolic 
syndrome and type II diabetes mellitus. Hypertension  is the major consequence  
of  chronic  renal  disease  which   develops  early  during  the  course  of  the  
disease
1
. Uncontrolled  hypertension  and  proteinuria  are  the  most  crucial  
risk  factors  for rapid  progression  of  kidney  disease  and  development  of  
extra  renal  complications  such  as cardiovascular  disease  and  stroke
2
.  Thus  
strict  control  of  blood  pressure  and  suppression  of proteinuria  are  the  
essential  goals  of  antihypertensive  therapy  in  patients  with  chronic renal  
disease. The  National  kidney  foundation  clinical  practice  guidelines  
recommend  a blood  pressure  goal of < 130mmHg systolic and < 80 mmHg 
diastolic  for  all  patients  with chronic  renal  disease
3
. 
                      Renin  angiotensin  inhibitors  such  as  ACE  (Angiotensin  
converting  enzyme) inhibitors  and  ARB (Angiotensin  receptor  blockers) are  
the  widely  recognized  renoprotective  agents. These  agents  effectively 
reduce  proteinuria  than  any  other antihypertensive  agents
4
. According  to  
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Japanese  society  of  hypertension  guidelines  they  are  recommended  as  first  
choice  treatment  for  hypertensive  patients  with  CKD
5
. But sometimes  it  is  
difficult  to  achieve  satisfactory  decrease  in  proteinuria  and  blood  pressure 
with  these  agents  alone
6
.  Combination  therapy  with  two  or  more  
antihypertensive  agents are  often  required  to  reduce  blood  pressure   to  
target  levels  in  these  patients
7
. 
                        Dihydropyridine  calcium  channel  blockers  are  one  of  the   
main  candidate  for combination  with  RAS  (Renin  Angiotensin  System)  
inhibitor  because  they  reduce  BP  even  in  patients  who  are  unresponsive   
to other  antihypertensive  agents
8
.  But  the  effect  of  these  drugs  on  
proteinuria  is inconsistent.  Traditional  CCB  (Calcium  channel  blocker)   
like  amlodipine act  by  blocking  L  type  calcium  channel  leading  to  
dilatation  of  afferent  arteriole  with  no effect  on  efferent  arteriole.  
Ultimately  renal  blood  flow  and  glomerular  pressure  increase accelerating  
proteinuria
9
.  Recently  developed  CCB,   cilnidipine  is  a  dual  blocker  of   L  
type  and  N  type  calcium  channel  and  thereby  dilates  both  afferent  and  
efferent arteriole.  Hence  renal  blood  flow  increases  without  increase  in  
glomerular  pressure thereby  reducing  proteinuria
6
. 
                    Renoprotective  effects  of  L  type  blockers   are  considered  less  
than  the  dual  L/N  type  blockers.  There  is  still  lack  of  clinical  trials  
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comparing   the  renoprotective  effects  of  various  calcium  channel  blockers. 
Thus  the  present  study  was  designed  to  compare  the  antiproteinuric  
effects  of   cilnidipine  and  amlodipine  as  add  on  therapy  to  losartan  in  
hypertensive  chronic  kidney  disease  patients.   
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DEFINITION: 
 
                        Chronic  kidney  disease/ Chronic  renal  disease  is  defined  
as structural  or  functional  abnormalities  of  the  kidney  for  ≥ 3  months  
manifesting  either  as   
1. Kidney damage  with  or  without  decreased  GFR  as  defined  by 
a)  Pathological abnormalities  
b)  Markers  of  kidney   damage   including    abnormalities   in      
composition of  blood   and   urine   or   abnormalities   in imaging  
tests 
                                                        or 
2. GFR  < 60 ml/min/1.73m
2
   with  or  without  kidney  damage
10
. 
                  A   cutoff   of    60 ml/min/1.73m
2
   is   selected  because 
a)     It  represents  a  reduction  to  approximately  half  of  normal  renal     
      function. 
b)      It   avoids  classification  of  older  individuals  who  may  have mild 
     reductions  in   their  glomerular  filtration  rate
11
. 
                    Chronic  renal  failure  represents  a  process  of  continuing  
significant   irreversible  reduction  in  nephron  number and  corresponds  to  
CKD  stages 3–5. 
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                    End  stage  renal  disease  corresponds  to  stage  of  CKD  that 
results  in   uremic  syndrome  due  to  accumulation  of  toxins, fluid    and 
electrolytes  which  are  normally  excreted  by  kidney 
RECOMMENDED   EQUATIONS  FOR  ESTIMATION  OF  GFR: 
1. Equation  from  the  modification  of  diet  in  renal  disease  study: 
 
              Estimated GFR = 1.86 x ( Pcr )
-1.154
 x ( age )
-0.203
 
 
              Multiply  by  0.742  for  women 
 
2. Cockcroft – Gault equation: 
 
             Estimated GFR =   (140 – age ) x body weight (Kg) 
 
                                                         72 x Pcr (mg/dl) 
 
            Multiply  by  0.85  for  women
1
. 
 
INCIDENCE  AND  PREVALANCE: 
 
                       The   estimated   prevalence   of   CKD   is   8 -16 %   
worldwide
12
. In   United  states ,   6% of  adult  population  are  in  stages  1 and 
2  and  4.5% are   in  stages  3 and  4
1
. Age  adjusted  incidence  rate  of  ESRD  
in  India  is  229 per  million  population  and  greater  than  1,00,000  new  
patients  enter  renal replacement   therapy  every  year
13
. Prevalence   of   
chronic   renal   disease   in India   was  estimated   to  be   0.78%
14
.  But  SEEK   
(Screening   and  Early  Evaluation  of  Kidney   disease ), a  community  based  
voluntary  screening  program  in  India    has  reported  very  high  prevalence  
6 
 
of  about  17.2%.  Prevalence  of  stage 1,2 ,3,4,5 CKD was  found  to  be   7%, 
4.3%,4.3%, 0.8%  and  0.8%  respectively.  The   most   frequent  cause  of  
CKD  is  diabetic  nephropathy  often  secondary  to  type  2  diabetes  mellitus  
which  contributes  to  30%  - 40% of  these  patients
15
. From   Indian   CKD   
registry  it  was  found  that  70%  were  males  , 73.6%  were  in  stage  4 – 5  
and  only  20 %  of  patients  with  ESRD  were  in  some  forms  of  renal  
replacement  therapy
16
. 
CLASSIFICATION: 
 
                      Classification  of  CKD  is  based  on  GFR   as  proposed  by  the 
 
Kidney  Disease  Outcomes  Quality  Initiative  (KDOQI)   Guidelines
17
. 
 
. 
 
STAGE 
 
DESCRIPTION 
 
GFR 
(ml/min/1.73m
2
) 
O 
Normal  or  increased  GFR  with  
risk  factors  for  CKD 
≥ 90 
1 
Normal  or  increased  GFR  with  
demonstrated  kidney  damage  
reflected by microalbuminuria, 
proteinuria,  hematuria  or  
histologic  findings 
≥ 90 
2 Mild  reduction  in  GFR 89 – 60 
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3 Moderate  reduction  in  GFR 59 – 30 
4 Severe  reduction  in  GFR 29 – 15 
5 
Renal  replacement  therapy  
required  in  the  form  of  dialysis  
or  transplantation  to  sustain  life 
< 15 
 
 
NATURAL  HISTORY  OF  CHRONIC  RENAL  DISEASE: 
                     Rate   of  progression  of  kidney  disease  varies  according  to 
individual   patients  and  underlying  pathology.  Patients   with   stage  3 – 5 
CKD eventually   progress  to  end  stage  renal  disease.  Rate   of   decline   in  
GFR  is found  to  be  rapid  in  patients  with  diabetic  nephropathy  averaging  
about        -10ml/min/year.  Effective   control   of   blood  pressure  slows  the  
rate  of progression   to – 5 ml/min/year. Patients   in   whom   both  glycemia  
and hypertension   are  optimally  controlled  further  improvement  can  be  
expected  (-1 to -2 ml/min/year )
18
. In  CKD  GFR  loss  averages  about  4 to 
10ml/min/year. For   every  1g  reduction  in  proteinuria  GFR  decline  is  
slowed  by  1- 2ml/min/year
19
.  Thus   effective   control  of   proteinuria  is  
mandatory. 
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RISK  FACTORS: 
A) SUSCEPTIBILITY  FACTORS: 
                          Factors   that   increase  susceptibility  to  kidney  damage  after 
exposure   to  initiation  factor. 
Genetic  predisposition                   
                   Alterations   or  polymorphism  of  genes  coding  for  putative 
mediators  including  RAS, NOS, kallikrein, cytokines ( IL – 1 & TNF – α ) , 
growth  factors ( PDGF,  TGF-β ), plasminogen  activator   inhibitor – 1  and  
complement  factors have  been  associated  with  increased  risk  of  CKD. 
Maternal – fetal  factors: 
                   Maternal  undernutrition  and  the  ensuing  fetal  malnutrition may   
contribute  to  the  development  of  hypertension,  metabolic  syndrome, 
diabetes  mellitus  and  CKD  in adult  life.  Low  birth  weight  causes  
reduction in  nephron  numbers   (oligonephronia)  thereby  the  ability  of  
nephrons  to handle   increased  solute  and  salt  load  is  reduced. 
Oligomeganephronia characterized   by  reduced  nephron  number  together  
with  glomerular  hypertrophy   has  been  implicated  in  the  pathogenesis  of  
CKD
18
. 
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Socio - economic  factors: 
                     Low  socio  economic  status  has  been  associated  with the  risk  
of  CKD. This   is  due  to  linkage of  poverty  with  diabetes  and  
hypertension. Thus   lower  income  and  social  deprivation  leads  to  
development  of  macroalbuminuria,  progressive  renal  function  loss  and  
ESRD.  They   also  have  less access to  renal  replacement  therapy
20
.  
B) INITIATION   AND  PROGRESSION  FACTORS: 
1. NON MODIFIABLE: 
Age and Gender: 
                     Elderly  patients  are  at  risk  of  faster  rate  of  decline  in  GFR. 
But  in  patients  with  type  1  diabetic  nephropathy , young  age  at  diagnosis  
is associated  with  rapid  progression  of  the  disease.  Males   are   more  
prone  for CKD   than  females. 
Race: 
                      In   United  States, incidence  and  prevalence  of   CKD  is  
higher in  the African – Americans  and  in  the  Hispanic Americans  than   the  
Caucasians. Similarly   disease   progression  is  also faster  in them. In  United  
Kingdom,  the Indo Asians  show  a  faster  rate  of  GFR  decline  than  
Caucasians. This  racial  predisposition  has  been  attributed  to  increased   
susceptibility  to  other  diseases  like  diabetes  mellitus  and  hypertension. 
10 
 
Genetics: 
                     Insertion/Deletion  polymorphism  in  ACE  gene  has  been  
linked to CKD  susceptibility  and  progression  as  well  as  responses  to  
antihypertensive drugs. 
Loss  of  renal  mass:   
                     The   threshold  for  natural  progression  of  the  disease  appears  
 to  be   crossed  when  reduction  in  nephron  function  exceeds  50%.  
Threshold  is  also   lowered  by  various  co – morbid  conditions  like  
hypertension,  obesity, diabetes   and  dyslipidemia. Diffuse   glomerular  
damage  carries  higher  risk  of rapid   progression  than  segmental  damage. 
2. MODIFIABLE: 
Hypertension: 
                        Systemic   hypertension  can  be  directly  transmitted  to 
glomerular  capillaries .  This  leads  to  development  of  glomerular  
hypertension which  can  initiate  glomerulosclerosis  and  CKD. 
Proteinuria/Albuminuria: 
                     Threshold   for  natural  progression  of  the  disease  is  crossed  
when   proteinuria   exceeds   500mg/day. The   risk  of  rapid  decline  in  GFR  
is high  with  non selective   proteinuria  than  with  highly  selective  
proteinuria. Also  urinary  albumin  creatinine  ratio  is  directly  proportional  
11 
 
to  the  presence and  severity  of  CAD and  CVD. Even  low  grade  
albuminuria  is  associated with  this  risk
18
. 
Metabolic  syndrome  
             It  consists  of  constellation  of  abnormalities  like  abdominal  obesity,   
dyslipidemia,  hypertension,  insulin  resistance,  hyperfiltration,  prothrombotic   
and  proinflammatory  states.  The  prevalence  of  CKD  is  high  in  patients  
with  2  or  more  components  than  patients  with  zero  or  1  component.  
Thus  there  exist  a  linear  relationship  between  number  of  components  of  
MS  and  presence  of  CKD
21
. 
Metabolic  factors: 
a)  Glycemia : 
                    The  risk  of  CKD  as  well as  its  progression  can  be  minimized 
by  excellent  glycemic  control. The   recommended  values  are  pre  prandial 
blood  sugar  to  be  maintained  between  90 – 130 mg/dl  and  HbA1c  less  
than 7 %
1
. 
b) Dyslipidemia  and  Obesity: 
                    Both  contributes  to  worsening  of  CKD. Weight  reduction 
lowers  obesity  related  renal  hemodynamic  changes  and  CKD  associated 
proteinuria
18
. Also  patients  with  high  triglyceride  and  low  HDL  levels  are  
prone  for  rapid  decline  in GFR
21
. 
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c) Hyperuricemia: 
                     Hyperuricemia  causes  hypertension  and  renal  injury  by  crystal 
independent  pathways  possibly  by  activating  RAS
18
.  Hyperuricemia  also  
decreases  nitric  oxide   production  provokating  endothelial  dysfunction,  
promotes  fibrosis  and  release  of  proinflammatory  cytokines
22
.   
Miscellaneous  factors: 
a)  Smoking  and  alcohol: 
                             Cigarette   smoking  and  alcohol  consumption  (exceeding  2 
drinks  per  day)  affect  renal  hemodynamics  leading  to  ESRD
18
. 
b) Analgesics: 
                        Analgesic  nephropathy  is  a  slowly  progressing   renal  disease 
characterized  by  chronic  nephritis  and  renal  papillary  necrosis
23
. Patient 
presents  with  decreased  concentrating  capacity  of  renal  tubule  and  sterile 
pyuria. Risk  factors  are  chronic  use  of  high  doses  of  combination  of  
NSAIDs  and  frequent  urinary  tract  infections. NSAIDs  cause  loss  of  
prostaglandin  induced  inhibition  of  both  reabsorption  of  chloride  and  
action  of  ADH ( leads  to  sodium  and  water  retention )
24
. It  also  suppress  
PGE2  mediated  compensatory  vasodilation  in  response  to  norepinephrine  
and  angiotensin II 
23
.   
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COMMON  ETIOLOGIES  OF  CHRONIC  KIDNEY  DISEASE: 
1. Primary  glomerular  diseases: 
                      It  includes  idiopathic  cresentic  glomerulonephritis,  primary  
focal  segmental  glomerulosclerosis  and  primary  mesangiocapillary  
glomerulonephritis. 
2. Tubulointerstitial  disease: 
• Chronic  heavy  metal  poisoning like  lead,  cadmium  and   mercury 
• Chronic  hypercalcemia  as  with  vitamin D  intoxication  and  
primary  hyperparathyroidism 
• Chronic  potassium  depletion  from  prolonged  use  diuretics 
without  potassium  supplementation  in  patients  with  ascites  or  
chronic  heart  failure. 
3.  Renal  vascular  disease:   
a.  Main  renal  artery  disease: 
                 Renal  artery  stenosis  which  may  be  due  to  atherosclerosis 
(common  in  elderly  males)  or  fibromuscular  dysplasia (common  in  middle  
aged  females). 
b. Renal  vein  disease: 
                      Bilateral  renal  vein  thrombosis  seen  in  patients  with  
nephrotic syndrome. 
14 
 
C.  Small  renal  vessel  disease: 
               Nephrosclerosis  secondary  to  long  standing  systemic  hypertension,  
polyarteritis  nodosa  or  malignant  hypertension. 
4.  Chronic  UTI: 
                 Chronic  pyelonephritis  which  may  be  due  to tuberculosis, E.coli. 
5.  Chronic  urinary  tract  obstruction: 
a. Upper  urinary  tract  obstruction: 
Bilateral  ureteric  or  renal  stones, ureteric  stricture  or  neoplasm. 
b. Lower  urinary  tract  obstruction: 
Bladder  stones,  bladder  tumour,  senile  prostatic  enlargement, stricture  
urethra. 
6. Collagen  diseases: 
• Systemic  lupus  erythematoses 
• Systemic  sclerosis 
• Polyarteritis  nodosa 
• Rheumatoid  arthritis 
7. Metabolic  diseases: 
• Diabetic  nephropathy 
• Gout  leads  to  CKD  either  directly  or  secondary  to  use  of  
NSAIDs 
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• Renal  amyloidosis  as  a   complication  of  familial  mediterranian  
fever  or  chronic  suppuration  like  osteomyelitis
25
. 
MECHANISMS  OF  PROGRESSION  IN  CKD: 
                  Three   main  mechanisms  are  involved  in  disease  progression. 
1.  Glomerulosclerosis 
2.  Tubulointestitial  fibrosis 
3.  Vascular  sclerosis 
GLOMERULOSCLEROSIS: 
               It  is  initiated  by  adaptive  changes  that  occur  in  normal  glomeruli 
of diseased  kidney.  In  response  to  an  insult  there  is  a  reduction  in  renal 
mass.  Compensatory  hypertrophy  of  remaining  glomeruli  occurs  in  order  
to maintain  renal  function. Glomerular  hypertrophy  is  associated  with 
hemodynamic  changes  like  increase  in  glomerular  blood  flow, 
hyperfiltration  and  transcapillary  pressure 
26
.  Hyperfiltration  is  
predominantly  mediated  by  preglomerular   vasodilation  leading  to  
enhanced  transmission  of  systemic  BP  to  glomerular  capillaries.  The  
resulting  impairment  of  autoregulation  contribute  to  glomerular  
hypertension
27
. All   these  changes leads  to  the  following  events. 
• Endothelial  injury  characterized  by  loss  of  anticoagulant  and  anti 
inflammatory  properties  and  acquisition  of  procoagulant  and 
16 
 
proinflammatory   poperties.  This  leads  to  attraction  and  activation  of 
platelets  and  microthrombus  formation. 
• Initiation  of  glomerular  microinflammation  and  formation  of  
glomerular tufts  by  inflammatory  cells  ( particularly  monocytes ). 
• Infiltrating  monocytes  stimulates  the  proliferation  of  mesangial cells 
either  by  direct  cell  to  cell  or  through  release  of  mitogens  leading  
to mesangial  hypercellularity. 
• Under  the  influence  of  fibrogenic  growth  factors  like  TGF – β  
activated  mesangial  cells  gets  converted  to  myofibroblast  expressing     
α - SMA  ( Smooth  muscle  actin )  and  synthesize  ECM ( extracellular 
matrix  components )  leading  to  ECM  deposition
18
. 
• Epithelial  injury  -  Podocytes  do  not  have  the  ability  to  replicate  in 
response  to  an  insult.  This  leads  to  decrease  in  podocyte  number.  
The remaining  podocytes  stretch  along  the  GBM  ( Glomerular  
basement membrane ) to  maintain  the  filtration   barrier  exposing  areas  
of  denuded GBM  that  would  interact  with  parietal  epithelial  cells  
forming  capsular  adhesions.  This  phenomenon  contributes  to  the  
development  of  proteinuria  and  segmental  glomerulosclerosis. 
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TUBULOINTERSTITIAL  FIBROSIS: 
                  It  is  the  major  contributor  for  progression  of  CKD. Thus  the  
decline  in  renal  function  has  a  better  correlation  with  extent of  
tubulointerstitial  damage  than  with  the  severity  of  glomerular  injury. 
Proteinuria  cause  direct  injury  and  activation  of  tubular  cells.  The  
activated  tubular  cells  in  turn  express  adhesion  molecules  and  elaborate  
proinflammatory  cytokines,  chemokines  and  growth  factors  that  contributes   
to  interstitial  fibrosis
26
.     
VASCULAR  SCLEROSIS: 
Vascular  sclerosis  is  the  key  feature  of  renal  scarring.  Renal   
scarring  is  associated  with   
• Loss  of  peritubular  capillaries  that  directly  correlates  with  fall  in  
renal  expression   of  proangiogenic  VEGF (Vascular  endothelial  
growth  factor). 
• Overexpression  of  thrombospondin  which  perpetuate  microvascular 
deletion  and  ischemia. 
• Ischemia  stimulates  tubular  cells  to  produce  ECM  components  
leading  to  vascular  sclerosis
18
. 
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PATHOPHYSIOLOGY: 
A. DISTURBANCE  IN  WATER  HOMEOSTASIS: 
                  In   early  stage  of  CKD,  kidney  loses  its  ability  to  
concentrate   urine  leading  to  polyuria  and  nocturia.  Nocturia  worsens  
uremic  symptoms  particularly  nausea  and  vomiting  by  causing  volume 
depletion.  This  phenomenon  is  called  as  morning  sickness  of  uremia.  
But  in  late  stage,  there  will be  loss  of   renal  ability  to  dilute  urine  
leading  to  fluid  overload
28
.  
B. DISTURBANCE  IN  SODIUM  EXCRETION: 
CKD  is  associated  with  disruption  of  glomerulotubular  balance 
(excretion  matches  intake)  of  sodium  such  that  dietary  intake  of  sodium  
exceeds  its  excretion  leading  to  sodium  retention  and  ECFV  expansion. 
This  expansion  can  contribute  to  hypertension. As  long  as  water  intake  
does  not  exceed  its  clearance, this  ECFV  expansion  will  be  isotonic  and  
plasma  sodium  concentration  remains  normal. If  glomerulotubular  balance  
of  water  is  disturbed,  water  retention  occurs  and  leads  to  hyponatremia. 
Thus  hyponatremia  is  not  commonly  seen  in  CKD  but  if  present  it       
responds  to  water  restriction
1
. Salt   losing   nephropathy   may  be  present  in  
some  patients. When  they  develop  fluid  loss  from  extrarenal  cause  they  
19 
 
are  prone  for  ECFV  depletion   causing  hypotension,  dehydration  and  
hypovolemia.  This  contributes  to  acute  on  chronic  kidney  failure
25
. 
C. ALTERATIONS  IN  POTASSIUM  HOMEOSTASIS: 
                      Potassium  excretion  is  mainly  mediated  by  aldosterone 
dependent  secretory  events  in  the  distal  segments. Thus  decline  in  GFR  is  
not  accompanied  by  decline  in  potassium  excretion. Hyperkalemia  in  CKD 
may  be  contributed  by  increased  dietary  intake  of  potassium, protein  
catabolism,  Hemolysis/Hemorrhage/Transfusion  of  red  blood  cells, 
metabolic  acidosis  and  drugs  like  ACE  inhibitors, β blockers and  
aldosterone  antagonist
1
. 
D.  ACID  BASE  DISORDERS:  
                      Metabolic  acidosis  is  common  in  patients  with CKD. In  early  
stages  it  is  due  to  decreased  ammonia  production  leading  to  non  anion  
gap  metabolic  acidosis
1
.  In   late  stages  due  to  decrease  in  GFR  there  will  
be  decrease  in  excretion  of   titratable   acid  causing  anion  gap  acidosis
25
. 
E. DISTURBANCE  IN  CALCIUM – PHOSPHATE  METABOLISM: 
Retention  hyperphosphatemia: 
                   Kidney  is  the  main  route  of  phosphate  elimination. When  GFR  
falls  below  30ml/min  phosphate  gets  accumulated  causing  
hyperphosphatemia. 
20 
 
Hypocalcemia: 
                   Serum  calcium  and  phosphate  are  always  in  dynamic 
equilibrium.  Hypocalcemia  occurs  with  any  increase  in  phosphate  levels. 
Hyperphosphatemia   also  causes  decreased   activation  of  vitamin  D  in  
PCT   which   also  contributes  to  hypocalcemia.          
Hyperparathyroidism: 
                Secondary   hyperparathyroidism  occurs  in  response  to  
hypocalcemia. Hyperphosphatemia   increases  parathyroid  hormone  secretion  
independent  of  calcium  levels  by  mechanisms  like  stimulation  of  
parathyroid  cell growth,  inducing  calcitriol  resistance  in  parathyroids  and  
direct  activation  of  PTH  secretion  leading  to  tertiary  
hyperparathyroidism.
29 
Vitamin  D  metabolites: 
                 CKD  is  associated  with  progressive  decline  in  activity  of  1 α  
hydroxylase  activity  leading  to  decrease  in  1, 25  dihydoxyvitamin   D3 
(active  form) levels  and  decrease  in  concentration  of  VDR (Vitamin  D  
receptor).  This  leads  to  secondary  hyperparathyroidism,  decreased  
intestinal  absorption  of  calcium,  defective  mineralisation  and  growth  
retardation
30
.   
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F.  RETENTION  OF  UREMIC  TOXINS: 
These  are   responsible  for  most  of  the  uremic  symptoms.
 
Uremic  
toxins   recognized  are 
1. Small, water – soluble , non – protein – bound  compounds, such  as  
urea. 
2. Small, lipid – soluble , protein – bound  compounds, such  as  phenols  
3. Larger  or  middle – molecules , such  as  beta2 – microglobulin  and       
    parathyroid  hormone
31
. 
G. ACTIVATION OF RENIN  ANGIOTENSIN ALDOSTERONE  
SYSTEM:                     
                    In  CKD  plasma  renin  activity  is  high  inspite  of  hypervolemia  
and  sodium  retention.  The  main  mechanism  involved  is  due  to  luminal  
narrowing  of  preglomerular  vessels  because  of  vascular  sclerosis,  
baroreceptors  in  JG  apparatus  will  measure  low  perfusion  pressures  
falsely  leading  to  increased  renin  release
30
.   
CLINICAL  MANIFESTATIONS: 
1. GASTROINTESTINAL  MANIFESTATIONS: 
Mouth: 
                In  saliva  urea  is  broken  down  to  ammonia  that  leads  to  
dysguesia  and  uremic  fetor  (urine  like  smell  in  breath). 
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Stomach : 
               Gastritis, peptic  disease, mucosal  ulcerations  occur  due  to  high  
concentration  of  urea  in  gastric  juice  that  cause  chronic  irritation  of  
gastric  mucosa. Gastrointestinal  bleeding  also  occurs. 
Intestine: 
               Constipation  is  more  common  in  CKD  due  to  dehydration. But  
diarrhea  also  occur  due  to  deposition  of  urea  in  colonic  mucosa  which  
leads  to  ulceration  that  is  liable  to  superadded  infections
25
. 
2. NEUROLOGIC  MANIFESTATIONS:  
CNS  effects: 
                They  become  evident  in  stage  3 CKD.  Early  symptoms  are  mild  
disturbances  in  concentration, memory  and  sleep. In  advanced  stage  
neuromuscular  irritability  including  hiccups, muscle  twitching,  
fasciculations occur. If  untreated  patient  develops  asterixis, myoclonus, 
seizures  and  coma. It  may  be  due  to 
• Disruption  of  balance  between  excitatory  and  inhibitory  neuronal   
pathways   by  organic  substances. 
• Guanidine  compounds  will act  as  agonist  at  NMDA  receptors  and 
antagonist  at  GABAA  receptors  leading  to  cortical  excitability. 
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• In  patients  with  CKD  asymmetrical  dimethyl  arginine  is  increased  
which  inhibits  endothelial  nitric  oxide  synthase
32
.   
Peripheral  neuropathy: 
              Peripheral  neuropathy  is  commonly  seen  in  patients  with  stage  4  
CKD. Initially  sensory  involvement  occurs  later  it  becomes  mixed. Also  
distal  parts  are  affected  more  than  proximal  and  lower  extremities  more  
than  upper  extremities
1
. CKD  is  often  associated  with  persistant  
hyperkalemia  that  cause  reverse  activation  of    Na
+ 
/ Ca
2+
  exchanger.  This  
leads  to  increased  influx  of  calcium  which  causes  continuous  membrane  
depolarization.  All  these  changes  contributes  to  axonal  degeneration  which  
leads  to  peripheral  neuropathy. 
Autonomic  neuropathy: 
Autonomic  neuropathy  may  be  due  to  
• Sympathetic  overactivity caused  by  increased  renal  afferent  signaling,  
tonic  arterial  chemoreceptor  activation  and  reduced  renalase  
production (newer  monoamine  oxidase  that  metabolises  
catecholamines) 
• Parasympathetic  hypoactivity  due  to  impaired  baroreceptor  sensitivity 
Induced   by   arterial  stiffness  and  vascular  calcification
33
. 
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• Autonomic   dysfunction   results  in  orthostatic  hypotension,  sweating  
abnormalities,  impotence  and  abnormal  response  to  valsalva  
maneuver
34
. 
Restless  leg  syndrome: 
                It  is  due  to  decrease  in  dopaminergic  modulation  of  intracortical  
excitability  with  decreased  supraspinal  inhibition  and  increased  spinal  cord  
excitability.  It  is  an  unpleasant  creepy  sensations  in  extremities  and  a  
compulsive  need  to  move  the  limbs
32
. 
Sleep  disorders: 
• Disruption  of  sleep  wake  cycle  leading  to  excessive  daytime  
sleepiness and  insomnia 
• Some  patients  develop  sleep  apnea due  to  pharyngeal  narrowing  that  
predisposes  to  upper  airway  occlusion. It  can  be  precipitated  by 
volume  overload  and  uremic  neuropathy  that  causes  impaired  upper  
airway  muscle  tone. 
• Periodic  limb  movements  of  sleep (PLMS)  characterized  by  
repetitive and  sudden  jerking  movements  of  lower  limbs  during  
sleep
35
. 
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3.HEMATOLOGICAL  MANIFESTATIONS: 
Anemia: 
                  Patients   usually  develop  normochromic   normocytic  anemia. The   
most   common  cause  is  relative  erythropoietin  deficiency  caused  by 
 Transformation   of   peritubular   fibroblast   to   myofibroblast    leading  
to   decreased    EPO   gene   expression
36
. 
 Diseased  kidney  adapts  to  an  increased  single  nephron  sodium  load   
by  attenuating  tubular  sodium  absorption.  This  leads  to  decreased                       
oxygen  consumption  and  improves  oxygenation  in  outer  medulla  and 
thereby  reduces  stimulus  for  EPO  deficiency.  
 Neutralisation  of  EPO  by  soluble  EPO – R  which  is  induced  by   
         inflammatory  mediators  like  IL – 6  and  TNF – α.    
 Inactivation  of  EPO  by  desalylation  mediated  by  proteases  which  is  
increased  in  uremic  patients
37
. 
Abnormal  homeostasis: 
                  Bleeding  tendency  is  increased  due  to  impaired  platelet 
aggregation  and  adhesion  to  endothelium  caused  by  defect  in  expression  
and activation  of  glycoprotein  adhesion  receptors,  reduced  quantities  of  
ATP, selective  defect  in  the  pool  of  deposited  serotonin  and  decreased  
synthesis  of  thromboxane  A2
36
. Thrombophilic  tendency  may  be  increased  
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in  certain  patients. After  activation  platelets  release  platelet  microparticles  
which  expose  procoagulant  proteins,  possess  membrane  receptor  for  
coagulation  factor  V  and  contains  high  amounts  of  negatively  charged  
phospholipids  on  outer  membrane  that  act  as  a  high  catalytic  surface  for  
prothrombinase  reaction
38
.   
4. CARDIOVASCULAR  MANIFESTATIONS: 
Hypertension: 
                       It   is  the  most  common complication  in  CKD. Hypertension   
is either  due  to 
 High  renin  secretion   
 Activation  of  baroreceptors  and  chemoreceptors  in  kidney  in  
response   to  pressure  changes  or  metabolites  from  ischemia  leading  
to  increased   renal  nerve  firing  that  contributes  to  centrally  mediated  
hypertension   by  activating  sympathetic  nervous  system  
 Increase  in  ET – A  receptor  expression  in  vascular  smooth  muscle  
cells that  causes  vasoconstriction  and  decreased  expression  of  ET – B 
receptor  in  endothelial  cells  causing  loss  of  negative  feedback  
inhibition  of  endothelin – 1.  
 CKD  is  associated  with  elevated  vasopressin  levels  which  act  on  
V1a  receptor  on  vascular  smooth  muscle causing  vasoconstriction  and  
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V2    receptor  that  promotes  water  reabsorption  by  inserting  aquaporin  
channels  in  collecting  duct
39
. 
Left  ventricular  hypertrophy:   
                    Left   ventricular  hypertrophy  is  characterized  by  increased  left 
ventricular  mass together  with  increase  in  size  of  individual  
cardiomyocytes and  cytosolic  calcium  . Initially   it   was   thought  to  be  an  
adaptive  response  to  increased  afterload (concentric  hypertrophy)  or  
volume  overload  (eccentric  hypertrophy)
36
.  Eventually   it   becomes  
maladaptive   with  an  imbalance  between   energy  expenditure  and  
production   causing  chronic  energy  deficit  and   myocyte  death.  In   CKD, 
LVH  is  also  associated  with  development  of  intramyocardial  fibrosis  
exacerbated  by  factors  like  male  gender,  ischemia,  aldosterone,  
angiotensin II  and  catecholamines.  Eventually, the  deleterious  effects  of  
hypertrophy,  increased  LV  chamber  pressure  and  fibrosis  dominate leading  
to  the  development  of  cardiomyopathy  and  LV  failure
40
. 
Dyslipidemia: 
                  Dyslipidemia  often  occurs  in stage  3  CKD.  It  is  characterized  
by  accumulation  of  partially  metabolized  VLDL  and  disturbance  in  
maturation  of  HDL.  Laboratory  findings  are  increased  triglycerides  and  
HDL
38
. LDL  levels  are  normal  or  elevated. 
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Ischemic  heart  disease 
CKD  patients  are  more  prone  for  accelerated  atherosclerosis   that  
leads  to  ischemic  heart  disease. Risk   factors    are   
 Hypertension, dyslipidemia  
 Increased  homocysteine  levels 
 Microinflammation  reflected  by  increased  concentration  of  high  
sensitivity  c – reactive  protein
36
  with  a  corresponding  fall  in  
negative  acute  phase  reactants  like  serum  albumin  and  fetuin
1
 
 Propensity  of  coronary  plaques  to  calcify  under  the  influence  of  
high  phosphate  concentration
36
. 
Congestive  heart  failure: 
It   can   be  a  consequence  of  diastolic  dysfunction  in  association    
with  LVH  or  systolic  dysfunction  caused  by  dilated  cardiomyopathy   or   
ischemia. 
Arrythmia: 
Both  atrial  and  ventricular  arrhythmias  can  occur. The  precipitating  
factors  are  LVH,  CAD,  electrolyte  disturbances  and  dialysis  associated  
hypotension  (more  common  in  patients  undergoing  hemodialysis)
41
. 
 
29 
 
5.  MUSCULO -  SKELETAL  MANIFESTATIONS:  
Bone  disease/ Renal  osteodystrophy  is  common  in  advanced  cases.   
Osteitis  fibrosa  cystica: 
It  is  due  to  secondary  hyperparathyroidism  and  stimulation  of  
osteoclast  by  PTH.  It  is  a  high  bone  turn  over  disease  characterized  by  
subperiosteal  lesions  and  osteoclastic  bone  resorption.  It  causes  proximal  
muscle  weakness,  bone  pain
42
  and  formation  of  brown  tumors
1
  ( bone  
cyst  with  hemorrhagic  elements ). 
Adynamic  bone  disease: 
It  is  a  low  bone  turn  over  disease  caused  by  iatrogenic suppression  
of  PTH ,  downregulation  of  PTHR1  leading  to  skeletal  resistance  to  PTH  
actions  and  inhibition  of  PTH  secretion  by  proinflammatory  cytokines.  It  
is  more  common  in  diabetics  and  possess  high  linkage  with  malnutrition   
inflammation  complex  syndrome (MICS)
43
. 
Osteomalacia: 
Osteomalacia  is  characterized  by  lack  of  bone  mineralization.  It  is 
due  to  aluminium  toxicity (chronic  ingestion  of  aluminum  containing  
phosphate  binders/Excess  aluminium  in  impure  dialysate  water)  or  
hypovitaminosis  D
42
. 
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Vascular  calcification: 
It  is  an active  process  characterized  by  de  differentiation  of  vascular  
smooth  muscle  cells  to  osteoblast  or  chondrocyte  like  cells. Later these  
cells  lay  down  extracellular  matrix  of  collagen  and  non  collagenous   
proteins  and  create  matrix  vesicles  or  apoptotic  bodies  that  attach  to  
ECM initiating  mineralization
44
. It  is  of  2  types 
 One  involves  intimal  layers  of  arteries  and  is  associated  with  
atherosclerotic  plaques  which  is  patchy  in  distribution  and  causes  
target  organ  ischemia  from  lumen  obstruction  or  plaque  rupture. 
 Other  type  involves  medial  wall  of  arteries  which  is  diffuse  that  
leads to  increased  vessel  stiffness  and  decreased  vascular  compliance  
contributing  to  LVH
43
. 
Calciphylaxis: 
                    It  is  also  called  calcific  uremic  ateriolopathy.  It  is  a  form  of  
vascular calcification  presenting  with  painful  nodules  that  advances  to 
ischemic necrosis.  The   main  etiology  is  deficiency  of matrix  gla  protein   
(MGP)    which  normally  inhibits  extraskeletal  calcification  by  modulating  
the activity  of  Bone  morphogenetic  protein – 2 (induces  vascular  
calcification) and  low  plasma  levels  of   fetuin  A.  MGP  activity  is   
inhibited   by  warfarin  leading  to  calciphylaxis
44
.    
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Myopathy: 
Muscle  wasting  occurs  mainly  in  the  proximal area  of  lower  limbs 
leading  to  waddling  gait
25
. It  is  mainly  due  to  metabolic  acidosis  that  
activates  ubiquitine  sensitive  proteasome  pathway  and  branched  chain  
amino  acid  dehydrogenase  in  skeletal  muscle  cells  causing  protein  
breakdown
45
.   
6. ENDOCRINE  MANIFESTATIONS: 
Thyroid  hormones: 
In   CKD  total  circulating  T3  concentration  is  reduced  due  to  
impaired  peripheral  conversion  of  T4  to  T3  and  loss  of  thyroid  binding  
globulin. But  clinical  hypothyroidism  is  extremely  rare  in  these  patients
46
. 
Insulin: 
Since  kidneys  are  the  major  route  of  elimination  of  insulin,  plasma  
half  life  of  exogenously  administered  insulin  is  increased. Thus  in  
diabetics  there  is  fall  in  the  requirement  of  insulin  as  kidney  function  
declines  progressively
47
. In  CKD,  patients  are  prone  for  insulin  resistance. 
Insulin  binding  to  its  receptor  and  receptor  density  remains  unchanged. 
But  the  contributing  factors  are 
 High  levels  of  adipose  tissue  derived  hormones  like  leptin,  resistin  
and adiponectin. 
 Presence  of  unidentified  nitrogenous  products
48
. 
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Sex  hormones: 
Males: 
                   In  stage  5  CKD  prolactin  levels  are  elevated  that  leads  to   
galactorrhoea. Patients  are  prone  for  testicular  failure   characterized  by  
erectile  dysfunction,  decreased  testosterone  and  reduced  spermatogenesis. 
Females: 
                   In  stage  4 – 5  pituitary  ovary  axis  is  disturbed. LH  levels  are  
raised  but  preovulation  surge  is  absent. So  the  cycles  will  be  anovulatory  
and  irregular
49
.      
Growth  hormone: 
                     CKD  patients  are  prone  for  growth  failure that  mainly  occurs   
due  to  GH  insensitivity  characterized  by  decrease  in  GH  receptors, post  
GH  receptor  defect  and  decreased  IGF – 1 syntheis
48
.   
Appetite: 
                    Appetite  is  suppressed  in  CKD  due  to  increased  leptin  levels   
and  increased  des  acyl  GHrelin  levels
46
. 
7. IMMUNOLOGICAL  MANIFESTATIONS: 
                      Infection  is  another  leading  cause  of  death  in  patients  with  
CKD  stage  5.  CKD  is  a  state  of  chronic  immunosuppression  with  both  
cellular  and  humoral  immunity  defects  like 
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 increased  levels  of  granulocyte  inhibitory  protein  I  and  II  that  
inhibits   
chemotaxis,  uptake  of  deoxyglucose,  oxidative  metabolism  and   
intracellular  killing  by  polymorphonuclear  leucocytes. 
 Increased  degranulation  inhibitory  protein  I  and  II  that  inhibits  
spontaneous  and  stimulated  polymorphonuclear  leucocytes  
degranulation. These  mechanisms  increases  susceptibility  to  
infections
50
. 
 Antibody  responses  to  immunization  is  poor. Thus  in  CKD  to  
increase  the  chance  of  seroconversion  Hepatitis  B  vaccine  should  
be  given  as  early  as  possible
38
.  
8. NUTRITIONAL  ABNORMALITIES: 
                        Protein   energy  malnutrition  is  more  common  in  patients  
with  stage  4 – 5  CKD.  It   is an   indicator  for  initiation  of  renal  
replacement  therapy
1
. The  main  causes  are  anorexia,  acidosis,  insulin  
resistance,  inflammation  and  urine  protein  loss
38
.   
9. DERMATOLOGIC  MANIFESTATIONS: 
                       In   CKD,  patients  develop  cutaneous  pigmentation  due  to   
deposition  of  retained  pigmented  metabolites  or  urochromes
1
.   Recently  
nephrogenic  fibrosing  dermopathy  has  been  reported  in  many  patients  
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which  is  characterized  by  progressive  subcutaneous  induration  in  arms  
and  legs.  It  can  be  precipitated  by  magnetic  resonance  contrast  agent  
gadolinium. Patients  are  also  prone  for  uremic  frost  characterized  by  
yellowish  tinge  on  skin  due  to  evaporated  urea  rich  sweat
51
.  Pruritis   can  
occur  from  skin  dryness  or   irritation  of  the  cutaneous  sensory  nerves  by   
calcium   deposits  or  by  parathormone
25
. 
10.  PULMONARY  MANIFESTATIONS: 
                       The  most  common  manifestations  are  uremic  lung  and  
uremic  pleuritis. Uremic  lung  characterized  by  batwing  perihilar  infiltrates  
represents  pulmonary  edema  and  is  caused  by  volume  overload  or  
myocardial  dysfunction
51
. 
EVALUATION  OF  PATIENTS  WITH  CHRONIC  KIDNEY  
DISEASE: 
I. History: 
 Family  history  should  be  elicited. Familial  renal  diseases  may  be    
monogenic (Polycystic  kidney  disease, Alport’s  disease, Medullary  
cystic  disease )  or  polygenic  ( Diabetes,  Hypertension, Obesity ) 
 Evaluation  of  appetite, recent  changes  in  weight, mental  acuity,    
memory,  mood,  any  change  in  sleep  pattern  should  be  done.  
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Changes  in  these  parameters  are  consistent  with  presence  of  uremic  
syndrome. 
 Analysis  of  all systems  should  be  done – urinary  symptoms 
(polyuria,  nocturia, frequency), Cardiovascular  system ( H/O  
MI/CHF), Peripheral  vascular  disease  (claudication,  peripheral  
ulcers), Musculoskeletal  complaints (muscle  wasting),  osteodystrophy  
(bone  and  joint  pain)  should  be  elicited.    
 Medication  history  to  rule  out  drug  induced  chronic  kidney  disease. 
History  of  intake  of  drugs  like  calcineurin  inhibitors,  lithium, 
pamidronate, chemotherapeutic  drugs, analgesics  are  to  be  elicited.   
II. Physical  examination: 
 Assessment  of  vital  signs – supine  and  upright  pulse  and  BP 
 Determine  the  volume  status 
A)  To  rule  out  volume  depletion  orthostatic  pulse  is  a  better  marker  than   
orthostatic  hypotension  because  orthostatic  hypotension  is  present  in 10%  
of  subjects  normally. Orthostatic  pulse  increase  of  more  than  30  beats/min  
indicates  less  severe  volume  depletion. Other  signs  are  dry  axilla,  dry  
mucous  membrane,  furrowed  tongue  and  flat  neck  veins. 
B)  To  rule  out  volume  overload  the  signs  are  hypertension,  peripheral   
edema,  pleural  effusion,  pulmonary  rales. 
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 Generalized  muscle  wasting  and  sallow  appearance  of  skin  are  
signs  of  advanced  CKD. 
 Evaluation  of  target  organ  damage 
A)  Cardiac  examination  to  reveal  LVH  or  decompensation 
B)  Carotid  pulse  for  bruits  to  rule  out  atherosclerosis
52 
C) Fundoscopic  examination  -  can  demonstrate   microaneurysms  and  
proliferative  retinopathy  diagnostic  of  diabetic  retinopathy  or  arteriolar  
narrowing,  arteriovenous  nicking,  hemorrhage  and  exudates  which  are   
characteristics  of  Hypertensive  retinopathy.  
D) Skin  changes  -  pallor,  scratches  and  excoriations  from  pruritis  and  
uremic  frost. 
E)  Perforation  of  nasal  septum   diagnostic  of  Wegener’s  granulomatosis  
or  cocaine  use 
F)  Abdominal  examination -  palpable  kidneys  observed  in  polycystic  
kidney disease,  palpable  bladder  suggestive  of  chronic  urinary  outlet  
obstruction  and  flank  mass  that  might  indicate  retroperitoneal  fibrosis  or  
tumours
53
. 
III. Laboratory  test: Blood 
 Complete  blood  count,  absolute  reticulocyte  count,  serum  ferritin,  
transferrin  saturation  
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 Blood  urea  and  creatinine  levels  -  usually  elevated 
 Serum  electrolytes -  Hyperkalemia  is  common 
 Serum  calcium and  phosphate  levels  -  Hypocalcemia  and  
Hyperphosphatemia  are  common 
 Markers  of  bone  formation  and  resorption  -  total  alkaline  
phosphatase levels  and  bone  specific  ALP  levels. 
 Lipid  panel  for  dyslipidemia 
 Serum  uric  acid  levels  for  hyperuricemia 
 Sedimentation  rate  and  C – Reactive  protein  to  assess  patient’s  
inflammatory  stage 
 Serological  testing  for  SLE  or  other  collagen  vascular  diseases, HIV  
panel,  Hepatitis  B/C
52
. 
Urine  analysis: 
 Urine  specific  gravity  is  low  and  fixed  at  1010.
25
 
 Hematuria  and  proteinuria  can  be  seen. Presence  of  oval  fat  bodies  
that  signifies  high  grade  proteinuria  and  dysmorphic  red  cells  
points  towards  glomerular  disease
53
. Low  grade  proteinuria  will  be  
seen  in  interstitial  disease  and  polycystic  kidney  disease
52
.  
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IV. Assessment   of  progression  of  disease: 
a) Estimation  of  glomerular  filtration  rate: 
It   is   the  measure  of  number  of  functioning  nephrons. It  indicates  
degree  of  kidney  injury  and  rapidity  of  progression.  It  is  estimated  from  
Cockcroft  and  Gault  or  MDRD (Levey)  formulas  which  are  based  on  
creatinine  clearance.  
Creatinine  is  the  metabolic  product  of  creatine  and  
phosphocreatinine  that  are  found  in  muscle.  It  is  freely  filtered  by  
glomerulus   and  a  small  amount  is  also  secreted.  Thus  creatinine  levels  
are  influenced  by  muscle  mass  and  gender. Hence  recently  new  
endogenous  compounds  have  been  evaluated  for  better  estimation  of  GFR. 
Serum  cystatin  C  is  a  basic  protein  of  cystatin  superfamily.  It  is  
synthesized  by  all  nucleated  cells  at  a  constant  rate. It  is  freely  filtered,  
not  secreted  and  not  influenced  by  muscle  mass,  gender  and  
inflammatory  process
54
. In  a  study  it  was  found  that  when  GFR  levels  
fell to  88ml/min/1.73m
2  
cystatin  levels  rose  but  creatinine  levels  did  not  
rise  until  GFR   dropped   to   75 ml/min/1.73m
2
.  Hence   cystatin   is   
considered   as  a  better   endogenous   marker  of  GFR
55
.  
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b)  Quantification  of  proteinuria: 
               Proteinuria  occurs  with  glomerular  damage. It  can  precede  
elevations  of  serum  creatinine  and  so  it  is  considered  as  an  early  marker  
of  kidney  damage. 
 Proteinuria – total  protein  excretion  rate  > 300mg/24hr. It  includes 
albumin  and  other  low  molecular  weight  proteins  like  globulin  and  
apoproteins 
 Microalbuminuria – albumin  excretion  rate  30 – 300 mg/day. 
Assessment of   albuminuria  is  a  better  indicator  than  proteinuria  as  
it  is  more  specific  for  glomerular  damage.     
Timed  collection: 
                      24  hour  collection  of  urine  is  the  best  method  for  
quantification  but  timed  sample  overnight  is  more  reliable  since  protein  
excretion  vary  throughout  the  day  and  with  postural  changes.   
Untimed  collection: 
                   Spot  urine  samples  are  used  and  the  values  are  expressed  as  
protein  or  albumin  creatinine  ratio.  It  is  more  convenient  and  not  affected   
by  posture  and  hydration  status. It  is  preferably  done  in  first  morning  
urine  samples (as  it  correlates  better  with  24 hr  protein  excretion)  but  
random  samples  are  also  accepted
56
. 
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Diagnostic  criteria: 
Total  protein  excretion  rate: 
 
Classification 
24 hour 
collection 
(mg/day) 
Spot urine 
dipstick 
(mg/dl) 
Spot urine 
protein 
creatinine ratio 
(mg/g) 
Normal <300 <30 <200 
Clinical 
proteinuria 
>300 >30 >200 
 
Albumin  excretion  rate 
 
 
      Normal  
 
<30 
 
<3 
 
<17(males) 
<25(females) 
 
Microalbuminuria 
 
30 – 300 
 
>3 
 
17 – 250 (males) 
25 – 355 (females) 
 
   Albuminuria  
 
>300 
 
NA 
 
>250 (males) 
>355 (females) 
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V. Imaging  studies: 
 Renal  ultrasonography  -  B/L  small  kidneys  suggestive  of  CKD  with   
scarring. Sometimes  kidney  size  might  be  normal  as  with  diabetic  CKD, 
amyloidosis  and  HIV  nephropathy. Kidney  size  is  increased  in  polycystic  
disease.  Discrepancy  in  size  of  more  than  1 cm  between  the  kidneys  
indicates  unilateral  disease  process
1
. Increase  echogenicity  is  also  
suggestive  of  chronic  medical  renal  disease
57
. 
 Doppler  sonography  to  rule  out  renovascular  disease 
 Voiding  cystogram  for  diagnosing  reflux  nephropathy 
 Echocardiogram  to  assess  cardiac  size,  LV  function,  regional  wall   
motion  abnormalities,  pulmonary  pressures  and  valvular  function 
 Radiological  bone  studies  to  assess  renal  osteodystrophy 
radiographic  contrast  imaging  should  be  avoided  in  CKD  for  fear  of  
contrast  induced  renal  failure
1
. 
VI. Renal  biopsy: 
It  is  indicated  for  the  following  reasons  in  CKD 
 To  find  out  if  the  underlying  cause  is  reversible  and  treatable 
 To  help  clinical  decisions  like  further  investigations,  selection  of  
renal  replacement  therapy 
 To  assess  prognosis
58
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 Unexplained  proteinuria  associated  with  progressive  renal  
dysfunction
57
. 
It  is  contraindicated  in  bilateral  small  kidneys  because  of  too much  
scaring  underlying  disease  may  not  be  apparent  and  associated  with  
increased  chance  of  bleeding
1
.   
TRIPLE  MARKER  APPROACH  FOR  DETECTION OF  CKD:  
This  approach  has  been  recently  introduced  and  the  parameters  
assessed  are  Cystatin  C  based  measure  of  GFR,  serum  creatinine  based  
GFR  estimation  and  urine  albumin  creatinine  ratio. 
CHRONIC  KIDNEY  DISEASE  BIOMARKERS: 
Plasma  Asymmetric  DiMethyl  Arginine (ADMA): 
It  is  an  endogenously  generated  methylated  arginine  that  possess  
inhibitory  activity  against  NOS. ADMA  levels  are  high  in  patients  with  
chronic  kidney  disease  and  is  associated  with  carotid  intima – media  
thickness,  left  ventricular  hypertrophy, cardiovascular  complications,  
progression  of  renal  disease  and  mortality  in  ESRD. 
Fibroblast  Growth  Factor  23 (FGF 23): 
FGF  23  is  secreted  by  osteoblast.  Physiologically  it  regulates  the  
activity  of  sodium  dependent  phosphate  cotransporters  at  the  brush  border  
membrane  of  proximal  tubule  and  helps  in  maintanence  of  phosphate  
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homeostasis. CKD is  associated  with  phosphate  retention  and  decrease  in  
calcium  and  activated  vitamin  D  levels.  FGF  23  is  elevated  in  CKD  and  
act  as  a  prognostic  indicator  for  cardiovascular  disease.  
Urinary  Monocyte  Chemoattractant  Protein – 1(MCP – 1) : 
Podocytes  and  tubular  cells  produce  MCP – 1  in  response  to  
proinflammatory cytokines,  high  glucose  levels  and  advanced  glycosylation  
end  products.  Thus  urinary  levels  of  MCP – 1  is  increased  in  diabetic  
CKD
59
. 
MANAGEMENT : 
Step 1. Establishing  chronicity: 
                 Factors  suggesting  chronicity  are  absence  of  severe  symptoms  
inspite  of  very  high  urea  and  creatinine  levels,  anemia  of  chronic  disease, 
sexual  dysfunction, skin  disorders, neurological  complications  and  small  
kidneys  on  renal  imaging
60
. 
Step 2. Attenuation  of  progression  of  CKD: 
Smoking  cessation: 
               Smoking  is  an  important  risk  factor  for  development  of  
microalbuminuria  and  overt  proteinuria. Risk  is  increased  with  high  daily  
consumption ( > 20 cig/day ), long  duration  (> 40 yrs)  and  high  cumulative  
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dose  (> 30 pack years). Smoking  cessation  reduces  the  risk  of  development  
of  CKD  and  progression  of  existing  CKD.   
Weight  loss: 
                    Weight  loss  as  little  as  10 lbs (4.5 kg)  results  in  reduction  of  
blood  pressure  and  glycemic  markers. Also  each  1 kg  loss  is  associated  
with  corresponding  110 mg  decrease  in  proteinuria  and  1.1 mg  reduction  
in  microalbuminuria  independent  of  BP  changes
61
. 
Dietary  sodium  intake: 
                    High  salt  intake  causes  activation  of  tissue  renin  angiotensin   
aldosterone  system  leading  to  renal  and  myocardial  fibrosis.  It  also  
overrides  the  antihypertensive  and  antiproteinuric  effects  of  drugs. Thus  
restriction  of  sodium  intake  is  advised.  Recommended  sodium  intake  in  
CKD  is  <1.5gNa
+
/day (65 mmol/day)
19
.    
Control  of  protein  intake: 
                    Protein  mediated  hyperfiltration  leads  to  rapid  decline  in  renal  
function. Thus  protein   restriction  is  recommended.  Dietary  protein  intake  
advised  is  0.6 – 0.75g/kg/day  and  it  should  be  of  high  biological  value. In  
stage  5  CKD,  spontaneous  protein  intake  is  reduced  and  the  patients  
become  prone  for  protein  energy  malnutrition. So  the  protein  intake  can  
be  increased  upto  0.9g/kg/day
1
. 
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Control  of  blood  pressure  and  proteinuria: 
The  goals  of  therapy  are  blood  pressure < 130/85  (<125/80 if  
proteinuria  is  >1gm/day), reduction  in  proteinuria  below  300mg/24hr  and  a   
loss  of  GFR  less  than  2ml/min  per  annum
62
. 
A. Angiotensin  Converting  Enzyme  inhibitors: (ACE inhibitors) 
ACE  Inhibitors  inhibit  the  cleavage  of  angiotensin-I  to  angiotensin-
II  (potent  vasoconstrictor).  They  also  inhibit  breakdown  of  bradykinin  
(which  is  a  potent  vasodilator  by  stimulating  release  of  nitric  oxide  and  
prostacyclin).  Both   these  mechanism  contribute  to  hypotensive  action
63
. 
They  decrease  both  arterial  and  venous  pressures  thereby  reduce  cardiac  
afterload  and  preload
64
. 
ACE  inhibitors  dilate  both  afferent  and  efferent  arteriole.  Thus  
provide  improved  intrarenal  hemodynamics  such  as  decrease  in  glomerular  
efferent  arteriolar  resistance  and  reduction  in  intraglomerular  capillary  
pressure
63
. Angiotensin II  stimulates  growth  factors  and  inflammatory  
cytokines  leading  to  glomerular  and  interstitial  sclerosis  and  also  induces  
glomerular  heparanase  causing  loss  of  glomerular  permselectivity.  ACE  
inhibitors  attenuate  these  angiotensin  II  mediated  intrarenal  pathways  
leading  to  renoprotection.   
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ACE  inhibitors  also  reduce  proteinuria  by  improving  the  
permeability  selectivity  of  filtering  membrane   and  thereby  ameliorate  the  
deleterious  effect  of  protein  exposure  on  tubular  cells,  podocytes  and  
mesangium
65
.  The  antiproteinuric  effects  are  independent  of  blood  
pressure  lowering  effect.  Thus  they  are  recommended  in  diabetics  even  in  
the  absence  of  hypertension
63
. The  renoprotective  effect  of  ACE  inhibitors  
are  directly  proportional  to  baseline  proteinuria. Thus  patients  with  high  
grade  proteinuria  benefit  more. But  patients  with   less  severe  proteinuria  
also  benefit  as  they  also  attenuate  the  progression  of  incipient  
nephropathy  (manifesting  with  microalbuminuria)  to  overt  nephropathy. 
They  also  induce  regression  towards  normoalbuminuria  from  
microalbuminuria.  Thus  they  are  effective  in  all  stages  of  renal  failure  in  
diabetic  patients
65
.   
Some  of  the  side  effects  of  ACE  inhibitors  are  non  productive  
cough,  hyperkalemia,  reduction  in  GFR  in  patients  with  atherosclerotic  
renovascular  disease  and  angioneurotic  edema
63
. 
B. Angiotensin II receptor  blockers: (ARB) Losartan: 
Mechanism  of  action: 
                     It   acts   by  causing   competitive  inhibition  of  AT1  receptor  
but  the  reaction  is  insurmountable (maximum  response  to  angiotensin  II  
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cannot  be  restored  in  the  presence  of  ARB  regardless  of  concentration  of  
angiotensin II ).  The   mechanisms  for  insurmountable  antagonism  are 
• Slow  dissociation  kinetics  of  drug  from  AT1  receptor 
• ARB  induced  receptor  internalization 
• Alternate  binding  sites  for  ARB  on  AT1  receptor 
Thus  insurmountable  antagonism  leads  to  sustained  receptor  blockade  
even  with  increased  levels  of  endogenous  ligand. It  has  high  affinity  for  
AT1  receptor  than  AT2  receptor. 
ARB  and  ACE  inhibitors  differ  in certain  aspects. 
• ARBs  reduce  activation  of  AT1  receptor  more  effectively  than  ACE 
inhibitors  because  ACE  inhibitors  do  not  block  non  ACE  angiotensin  II 
generating  pathways 
• ARBs  permit  activation  of  AT2 receptors.  Most  of  the  biological 
effects of  angiotensin II  like  contraction  of  vascular  smooth  muscle,  
rapid  and  slow  pressor  responses,  aldosterone  secretion, release  of  
adrenal  catecholamines, enhanced  noradrenergic  neurotransmission, 
increased  sympathetic  tone, changes  in  renal  function,  cellular  
hypertrophy  and  hyperplasia  is  mediated  via  AT1 receptor. AT2 
receptor  counterbalances  the  actions  of  AT2  receptor.  AT2  receptor  
possess  antiproliferative, proapoptotic, vasodilatory, natriuretic  and  
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antihypertensive  effects. ARBs  stimulate  renin  release  and  so  
increased  amounts  of  angiotensin II  is  available  to  activate  AT2  
receptor.   
• ACE  inhibitors  increase  Ang (1-7)  levels  more  than  ARBs  because 
Ang (1-7)  is  cleared  by  angiotensin  converting  enzyme.  
• ACE  inhibitors  increase  levels  of  many  ACE  substrates  like  
bradykinin which  is  responsible  for  cough  and  angioneurotic  edema. 
ARBs  are  less  prone  for  these  adverse  effects
66
. 
Renal  effects  of  AT1  blockade: 
 Renal  hemodynamics -  decrease  renal  blood  flow, decrease  renal 
vascular  resistance, variable  effects  on  GFR  depending  on  BP, 
improved  autoregulation, decreased  efferent  arteriolar   resistance, 
reduction   in intraglomerular  capillary  pressure. 
 Renal  tubular  function – reduction  of  sodium  and  fluid  reabsorption,  
normalizes  acidification  and  bicarbonate  excretion, blocks  stimulation  
of  aquaporin  channels
67
. 
 Glomerular  permselectivity – improves  charge  selectivity  of  
glomerular  basement  membrane , reduction  in  mesangial  uptake  and  
clearance  of  macromolecules.  These  effects  contribute  to  reduction  
in  proteinuria
68
. 
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 Renal  fibrosis – blocks  ECM  deposition  in  the  mesangium,  
attenuates  fibroblast  proliferation  and  transformation. 
 Inflammation – blocks  proliferation  of  leukocytes  and  upregulation  of  
adhesion  molecules,  decreased  generation  of  reactive  oxygen  
species
67
. 
Pharmacokinetics:  
Oral  bioavailability  of  losartan  is  33%. It  undergoes  first  pass  
metabolism  with  CYP450 2C9 and  3A4  and  gets  converted  to  active  
metabolites
66
.    Carboxylic  acid metabolite  EXP 3174  is  one  among  them  
which  is  more  potent  than  the  parent  drug  and  a  reversible  non  
competitive  inhibitor  of  AT1  receptor. Losartan  achieves  peak  plasma  
concentration  in       1 – 3  hrs.  The  plasma  t1/2  of  losartan  and  EXP 3174  
are  2.5 and  6-9 hrs  respectively.  Elimination  is  by  renal (40%)  and  biliary  
(60%)  excretion
67
. Thus  its  plasma  concentration  is  affected  by  hepatic  
and  not  by  renal  insufficiency.  It  is  administered  at  a  dose  of  25 – 
100mg  once  or  twice  daily
66
. 
Adverse  effects: 
 ARBs  have  long  onset  of  action  of  about  4 - 6 wks. This  avoids  
first dose  hypotension  and  rebound  hypertension  seen  with  other  
drugs
68
. 
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 Cough  and  angioedema  less  than  ACE  inhibitors 
 Acute  renal  failure  in  patients  with  renal  artery stenosis 
 Hyperkalemia (in  renal  disease/combined  with  K
+
  supplements  or  K
+
  
sparing  diuretics) 
 Post  marketing  reports  of  anaphylaxis, hepatitis, neutropenia,  
leucopenia, agranulocytosis, pruritus, urticaria  and  vasculitis
66
.   
ARBs  versus  ACE  inhibitors: 
                    Hypertensive  patients  with  normal  or  impaired  renal  function  
treated  with  ARBs  exhibit  renal  responses  similar  to  ACE  inhibitors. 
Antiproteinuric  effects  are  also  similar. Both  the  dugs  exhibit  
antiproteinuric  effects  in  diabetic  and  non  diabetic  kidney  disease  and  
also  in  renal  transplant  recipients.  Maximal  antiproteinuric  effects  are  
obtained  in  3 – 4 weeks.  Thus  studies  in  CKD  have  found  no  differences  
in  the  efficacy  of  ACE  inhibitors  or  ARBs
68
.  Few  randomized  trials  have  
shown  that  ACEI  are   renoprotective  in  type  1  diabetes, type 2  diabetes  
with  microalbuminuria  and  nondiabetic  CKD. But  ARBs  are  more  
renoprotective  in  type 2  diabetes  with  microalbuminuria  and  overt  
nephropathy 
69
 . When  these  drugs  are  given  in  doses  higher  than  
recommended  maximum   it  results  in  greater  lowering  of  urine  protein  
levels  without  further  reduction  in  BP
22
 . One  additional  property  seen  
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with  losartan  that  is  not  seen  with  other  drugs  is  induction  of  uricosuria.  
Uricosuric  effect  is  independent  of  RAAS  inhibition  and  is  not  associated  
with  risk  of  nephrolithiasis. This  reduction  in  serum  uric  acid  levels  
contribute  to  additional  renoprotective  effect
68
.  
C. Calcium  channel  blockers(CCB): 
Amlodipine: 
Mechanism  of  action: 
                      It  is  a  third  generation  dihydropyridine  type  of  CCB  with  
stable  pharmacokinetics  and  less  cardioselective
70
 . Voltage  gated  L – type   
calcium  channel  is  the  dominant  type  found  in  cardiac  and  smooth  
muscle.  It  is  comprised  of  α1  (larger  pore  forming  subunit) , α2 ,  β, γ  and  
δ subunits.  Amlodipine  act  by  binding  to  one  site  on  α1 subunit. The  drug  
acts  from  inner  side  of  the  membrane  and  bind  effectively  to  open  and  
inactivated  channels.  This  binding  leads  to  reduction  in  the  frequency  of  
opening  of  channels  in  response  to  depolarization. This  results  in  marked  
decrease  in  transmembrane  calcium  current  through  these  channels  leading  
to  decrease  in  total  amount  of  calcium  reaching  the  intracellular  store.  
Pharmacological  effects: 
Vascular  smooth  muscle: 
                    Vascular  smooth  muscles  are  highly  dependent  on  
transmembrane  calcium  influx  to  maintain  normal  resting  tone  and  for  
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contractile  responses. Amlodipine  by  blocking  transmembrane  calcium  
influx  causes  long  lasting   smooth  muscle  relaxation  that  leads  to  
reduction  in  peripheral  vascular  resistance  and  fall  in  blood  pressure. 
Arterioles  are  more  sensitive  to  hypotensive  action  than  venules. It  also  
has  a  greater  ratio  of  vascular  smooth  muscle  effects  relative  to  cardiac  
effects
71
. 
 Cardiac  muscle: 
Due  to  gradual  onset  of  action  and  long  duration  effects  it  causes  
less  activation  of  sympathetic  nervous  system  and  hence  heart  rate  is  
unaffected. In  general  amlodipine  does  not  cause  any  change  to  
sympathetic  nervous  system  although  it  appears  to  suppress  baroreceptor  
mediated  activation  of  sympathetic  nervous  system    but  this  sympatholytic  
activity  is  less  effective  than  cilnidipine
72
. They also  dilate   coronary  
arteries  leading  to  increase  in  coronary  blood  flow
68
.  
 Renal  effects: 
L- type  calcium  channels  are  abundant  in  afferent arteriole  but  not   
in  efferent  arteriole. Amlodipine  dilate  afferent  arteriole  directly  than  
efferent arteriole  resulting  an  increase  in intraglomerular  pressure. Filtration  
fraction  which  parallels  the  change  in  intraglomerular  pressure  is  also  
increased. Now  amlodipine  is  thought  to  blunt  glomerular  hypertension  
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due  to  their  systemic  BP  lowering  effect  as  systemic  blood  pressure  is  
directly  transmitted  to  afferent  arteriole. But  this  effect  is  inconsistent  and  
varies  with  patients
73
. Long  term  effects  have  shown  that  only  few  
patients  exhibit  no  change  in  GFR  but  others  exhibit  exaggerated  increase  
in  GFR  and renal  plasma  flow. Proteinuria  is  not  decreased  but  
paradoxically  increased  in  some  cases  due  to  increased  glomerular  
capillary  pressure. It  also  exhibits  natriuretic  effect  mediated  by  direct  
inhibition  of  renal  tubule  sodium  and  water  absorption
74
. 
Pharmacokinetics: 
                     It  has  high  oral  bioavailability  (60-80%).  Onset  of  action  is   
gradual  due  to  intermediate  rate  of  drug  absorption. Peak  plasma  
concentration  is  achieved  in  6-8 hrs. Its  t1/2  is  30 – 50  hrs
71
. It  is  
extensively  plasma  protein  bound  and  eliminated  via  liver
75
.   
Cilnidipine : 
Mechanism  of  action: 
                       It  is  a  unique  dihydropyridine  classified  as  fourth generation  
calcium  channel  blocker.  It  is  a  dual  blocker  of  L  type  and  N  type  
calcium  channel. N  type  is  widely  distributed  in  nervous  system. 
Cilnidipine  by blocking  N type  channels  blocks  the  release  of  sympathetic  
neurotransmitter.  Thus  it  possess  antisympathetic  property  in  additional.  
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Pharmacological  effects: 
Vascular  smooth  muscle: 
Cilnidipine   relaxes  vascular  smooth  muscle  by  calcium channel  
antagonism   and  activation  of  eNOS  that  leads  to  production  of  nitric  
oxide. It  exhibits  slow  onset  and  long  lasting  antihypertensive  action.  Pure  
L – type  calcium  channel  blockers  due  to  their  potent  vasodilatory  
property prompts  a  rapid  compensatory  increase  in  sympathetic  nervous  
activity  mediated  by  N  type  calcium  channel. This  reflex  leads  to  release  
of  norepinephrine  that  produces  vascular  contraction, tachycardia  and  
activation  of  RAAS. Cilnidipine  by  blocking  N  type  channel  counteracts  
these  responses  and  reduces  the  risk  of  cardiovascular  disease. Thus  
cilnidipine  exhibits  significant  hypotensive  action  without  causing  reflex  
tachycardia.  
Cardiac  effects : 
It  is   a  more  potent  coronary  vasodilator . During  schemia  and  
reperfusion  periods,  cilnidipine   leads  to  reduction  in  myocardial  infarct  
size  and  incidence  of  ventricular  premature  beats  by  decreasing  
myocardial  interstitial  norepinephrine  levels. It  also  causes   abbreviation   of  
abnormally  prolonged  ventricular  repolarization, decrease  in  BNP, LV  mass  
index, heart  rate  and  cardiothoracic  ratio. As  it  possesses  high  vascular  
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selectivity  it  does  not  depress  cardiac  functions  like  contractility,  SA  
node  automaticity  and  AV  node  conductivity  like  previous  CCBs.   
Antioxidant  property: 
                All  CCBs  act  as  lipophilic  chain  breaking  antioxidant. 
Lipophilicity  of  cilnidipine  is  very  much  greater  than  amlodipine  such  
that  it  suppresses  the   oxidative  stress  independent  of  N  type  blockade. 
Cilnidipine  also  inhibits  NADPH  oxidase  derived  superoxide  formation  in  
kidneys  whereas  amlodipine  does  not. N  type  calcium  channels  in  
podocytes  play  an  important  role  in  angiotensin  II  induced  superoxide  
formation. Cilnidipine  counteracts  this  and  elicits  podocyte  protection.  
Renal  effects: 
                    The  renal  nerve  stimulation  leads  to  release  of  norepinephrine   
that  activates  adrenoceptors  in  the  vascular  vessels, renal  tubular  cells  and 
granular  cells  of  the  juxtaglomerular  apparatus  and  thereby  induces  renal  
vasoconstriction, anti-natriuresis  and  renin  secretion  respectively.  These  
effects  can  be  suppressed  by  cilnidipine. Sympathetic  nerves  are  
distributed  in  both  afferent  and  efferent  arteriole. Cilnidipine  dilates  both  
afferent  and  efferent  arterioles  leading  to  reduction  in  glomerular  capillary  
pressure,  afferent  and  efferent  arteriole  resistance, and  glomerular  volumes. 
Filtration  fractions  remain  unchanged  or  decreased. It  also  suppresses  
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glomerular  hypertrophy  and  interstitial  fibrosis. Amelioration  of  glomerular  
hypertension  and  antioxidant  property  both  contribute  to  antiproteinuric  
effects. Thus  cilnidipine  retards  the  progression  of  renal  disease. 
Other  effects: 
 Cilnidipine  decreases   the  production  of  aldosterone  from  
adrenocortical  cells  and  reduces  plasma  levels  of  angiotensin II  and  
aldosterone. 
 Downward   shift  of   the   lower   limit  of   autoregulation   for  cerebral  
blood  flow, reduction  of    cerebral  infarction  size  and   increase  in        
cerebral  blood  flow.  
 Improves  insulin  resistance. 
 Cilnidipine  also  causes   reduction  in  uric  acid  levels. This  also  
contributes  to  renoprotection .  
 Also  causes  attenuation  of  platelet  activation  as  catecholamines  
induce  platelet  activation  via  α2  receptor
76
. 
Adverse  effects  of  calcium  channel  blockers: 
 Peripheral  edema  -  results  from   increased  hydrostatic  pressure  in  
lower  extremities  due  to  precapillary  dilation and  reflex  post  
capillary  constriction . Cilnidipine  does  not  cause  peripheral  edema  
as  it  dilates  both  precapillary  and  post  capillary  beds. 
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 Headache, nausea, dizziness, flushing -  related  to  vasodilation (less  
with  amlodipine  and  cilnidipine) 
 Gingival  hyperplasia 
 Worsening  of  gastroesophageal  reflux  disease – due  to  inhibition  of  
contraction  of  lower  esophageal  sphincter 
 Rash, constipation 
 Elevated  liver  enzymes.
75
 
Advantages  of  calcium  channel  blockers  in  clinical  use: 
                              CCBs  are  generally  well  tolerated.  They  do  not  cause  
electrolyte derangements, alteration  in  glycemic  or  lipemic  control, sexual  
dysfunction  and  orthostatic  hypotension  ( as  venoconstriction  is  intact). 
Most  of  the  CCBs,  especially  long  acting  agents  reduce  heart  rate, 
improve  myocardial  oxygen  demand,  conserve  contractility  and  improve  
ventricular  filling. Thus  they  are  mainly  used  as  antihypertensive  agents  in  
CKD  with  metabolic  disorders  like  diabetes, peripheral  vascular  disease  
and  stable  IHD. They  are  also  ideal  agents  for  elderly  patients   as  they  
tend  to  lower  the  risk  of  stroke.  Newer  CCBs  have  additional  effect  of  
reducing  proteinuria , maintaining  GFR  and  retarding  progression  of  
CKD
74
.   
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D. Direct  renin  inhibitors (DRI) : 
                   DRI  inhibits  RAAS  at  its  rate  limiting  step ( conversion  of  
angiotensinogen  to  angiotensin I )  and  therefore  achieve  complete  blockade  
of  RAAS
61
. They  do  not  cause  reactive  increase  in  renin  and  so  plasma  
levels  of  angiotensin  II  is  not  elevated. They  cause  dose  dependent  
decrease  in  systolic  and  diastolic  blood  pressure, also  reduce  proteinuria  
and  reverse  left  ventricular  hypertrophy. Thus  provide  comparable  
renoprotection  as  an   ACE  inhibitor  and  ARB
74
. 
E. Aldosterone  antagonist:  
                 Aldosterone  is  an  important  mediator  of  progressive  renal  injury   
through  hemodynamic  and   profibrotic  actions
61
. Aldosterone  antagonist  
blocks  sodium  and  water  retention  leading  to  reduction  in  blood  pressure  
and  also  reduces  proteinuria  independent  of  BP  lowering  effect
68
. Their  
actions  are  generally  additive  to  ACE  inhibitors  or  ARBs  and  monotheray  
with  these  drugs  are  not  preferred. But  they  increase  the  risk  of  
hyperkalemia  when  co  administered  with  these  drugs
61
. 
F. Beta  blockers: 
                     They  act  via  attenuation  of  sympathetic  stimulation   through  
competitive  antagonism  of  catecholamines  action  at  β  adrenergic  receptors. 
They  cause  reduction  in  GFR  and  suppression  of  plasma  renin  activity. 
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They  do  not  have  significant  action  on  proteinuria. They  are  mainly  used  
as  secondary  therapy  in  patients  with  CKD  with  specific  comorbidities  
like  heart  failure, post  myocardial  infarction  and  angina. It  is  also  found  
that  reduction  in  major  cardiovascular  events  associated  with  beta  
blockers  is  not  seen  in  elderly  patients.  Hence  they  are  not  recommended  
as  first  line  agents  in  elderly  patients.   
E. Diuretics: 
                Diuretics  are  usually  employed  in  CKD  to  control  blood  volume   
and  to  reduce  edema  formation. When  serum  creatinine  reaches  2 mg/dl  
volume  reduction  is  better  with  loop  diuretics  than  with  thiazide  diuretics. 
The  renal  clearance  of  loop  diuretics  fall  in  parallel  with  GFR  because  
of  accumulation  of  organic  acids  that  compete  for  proximal  secretion  and  
reduced  renal  mass.  But  the  maximal  increase  in  sodium  excretion  is  
maintained  due  to  increased  expression  of  NA
+
/K
+
/2 Cl
-
  cotransporters. 
Thiazide  diuretics  are  ineffective  if  creatinine  clearance  is  <35ml/min
74
. 
Thiazides  when  used  with  loop  diuretics  in  patients  with  GFR 5 – 15 
ml/min/1,73m
2
  significantly  reduces  the  dose  of  loop  diuretics. For  this  
metalazone  is  usually  preferred
77
. 
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Step 3: Management  of  complications: 
A. Treatment  of  hyperkalemia: 
                   Reduction  in  serum  potassium  is  required  if  it  exceeds  
7mmol/l  due  to  risk  of  cardiac  arrest. Emergency  treatment  is  started  with  
10 ml  of  10%   calcium  gluconate   over  10  mins  intravenously. 
Furthermore  intravenous  glucose  ( 50 ml of 50% dextrose )  combined  with  
10 U  of  short  acting  regular  insulin  can  be  given  for  greater  decline  in  
potassium  levels. Hyperkalemia  can  also  be  corrected  using  β2  adrenergic  
agonist  (salbutamol  0.5 mg  in  100ml  of  5%  dextrose  over  15 mins  
infusion). Less  severe  cases  can  be  treated  with  slowly  acting  ion  
exchangers  ( sodium/calcium  polystyrene  sulphonate ), dietary  potassium  
restriction  and  prompting  diuresis  using  loop  diuretics
60
.   
B. Treatment  of  metabolic  acidosis:  
HCO3
-  
 concentration  should  be  maintained  above  20 mEq/l.  This  
can  be  achieved  with  modest  amounts  of  alkali  ( 1 – 1.5 mEq/kg/day ). 
Alkali replacement  prevents  deleterious  effect  of  prolonged  positive  H
+
  
balance  like progressive  catabolism  of  muscle  and  loss  of  bone. Both  
sodium  citrate  and  sodium  bicarbonate  are  equally  effective
78
.  But  sodium  
citrate  enhances  the  absorption  of  aluminium  and  so  should  not  be  given  
to  patients  taking  aluminium  containing  phosphate  binders. Also  sodium  
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retention  and  hypertension  is  less  when  sodium  is  given  with  
bicarbonate
60
. 
C. Treatment  of  anemia: 
Erythropoiesis  Stimulating  Agents (ESA): 
The  target  goal  is  to  keep  Hb  level    between  11-12 g/dl. To  
achieve  this  ESA  are  used. It  has  been  shown  that  correcting  anemia  with  
ESA  is  associated  with  improvements  in  left  ventricular  mass  index  and  
electrophysiologic  markers  of  cognitive  function.  First  generation  agent  is  
epoetin α. It  can  be  given  subcutaneously  or  intravenously. Sustained  levels  
of  the  drug  is  required  to  trigger  erythroid  differentiation  and  to  avoid  
neocytolysis (premature  phagocytosis  of  nascent  RBC  in  the  absence  of  
circulating  EPO).  Subcutaneous  administration  provides  more  sustained  
levels  and  so  less  frequent  dosing  is  required  than  intravenous  route
37
. 
Epoetin α  is  given  at  a  dose  of  80 – 120 U/Kg  SC  thrice  weekly. It  leads  
to  gradual  rise  in  hematocrit  over 2 – 4 months. Hematocrit  beyond  36%  is  
not  recommended  as  it  is  associated  with  high  incidence  of  myocardial  
infarction  and  death. The  most  common  adverse  effect  is  aggravation  of  
hypertension. Recently  darbepoetin α  has  been  introduced  which  is  
classified  as  second  generation  agent. It  has  a  better  pharmacokinetic  
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profile  and  is  administered  at  a  dose  of  0.45 µg/kg  subcutaneous  once  
weekly
79
. 
ESA  hyporesponsiveness:  
It  is  defined  as  continued  need  for  recombinant  human  
erythropoietin  agents  at  doses  of  450 U/kg  per week  intravenous  EPO or      
300 U/kg  per  week  subcutaneous  or 1.5 mcg/kg per week  of  darbepoetin  
alfa  subcutaneous
31
.  The  most  common  causes  are  inflammation  and  
absolute  iron  deficiency. MIC  syndrome  ( Malnutrition  and  inflammation  
complex )  in  CKD   is  associated  with  increased  cytokines  that  blocks  the  
effect  of  rHuEPO on  erythroid  differentiation
37
.  Absolute  iron  deficiency  
may  be  due  to  external  blood  loses  or  exhaustion  of  iron  stores  due  to  
increased  erythropoiesis  from  EPO  therapy
31
.   
Iron  supplementation: 
Per   oral  treatment  is  ineffective  due  to  dialysis  associated  loses  of  
iron  and  high  levels  of  hepcidin  in  CKD  that  blocks  duodenal  uptake  of  
iron. But  still it  is  easy  to  administer, cheap  and  associated  with  less  
adverse  effects. In  parenteral  therapy, ferric  gluconate  is  better  than  iron  
sucrose  and  dextran  as  it  donates  iron  more  readily  to  apotransferrin  and  
increases  the  efficiency  of  erythropoiesis. In  addition  to  this  iron  sucrose  
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can  cause  injury  to  proximal  tubular  cells  and  thereby  increase  the  
incidence  of  albuminuria
37
. 
D. Treatment  of  bleeding  diathesis: 
The  main  goal  is  to  restore  bleeding  time  less  than   6 mins. This  
can  be  achieved  using  infusion  of  vasopressin  (0.3µg/kg  in  100 ml  0.9% 
saline  in  30  mins).  A  more  prolonged  effect (up to 14 days) can  be 
obtained  by  intravenous  oestrogens  in  a  dose  of  0.6 mg/kg daily for 5 days.   
This  can  be  also  corrected  by  hemodialysis
60
. 
E. Treatment  of  renal  osteodystrophy:  
The  targets  are  to  reduce  PTH < 150 pg/ml, phosphate  concentration 
< 4.5 mg/dl  and  vitamin D 30 ng/ml
80
. 
Phosphate  binders: 
Hyperphosphatemia  is  common  in  CKD. Hence  phosphate  binders  
are  used. Calcium  containing  phosphate  binders  are  cheap  but  can  cause  
hypercalcemia  and  promote  vascular  calcification. Sevelamer  and  
lanthanum are  used  as  they  are  highly  potent  and  cause  less  
hypercalcemia. This  treatment  should  always  be  combined  with  dietary  
phosphate  restriction  to  reduce  pill  burden. 
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Vitamin D: 
Vitamin  D  therapy  is  aimed  at  achieving  adequate  levels  of  25 
(OH)D, reducing  PTH, restoring  bone  histology  to  normal. Vitamin  D  
reduces  the  production  of  inflammatory  cytokines  from  monocytes. Also  
local  extra renal  tissue  conversion  of  25 (OH) D  to 1,25 (OH)2 D  is  needed  
for  regulation  of  immune  responses, oxidative  stress  and  blood  pressure.  
Nutritional  vitamin  D  therapy  is  less  effective  in  reducing  PTH  and  
restoring  bone  histology. Ergocalciferol  is  usually  used  to  achieve  the  
aims. If  despite  adequate  25(OH) D  level, PTH  remains  elevated  active  
vitamin  D  therapy  in  the  form  of  calcitriol  or  vitamin  D  analogs  are  
used. They  lower  PTH  and  improve  bone  histology. But  they  cause  
hypercalcemia  and  hyperphosphatemia  in  a  dose  dependent  manner. 
Calcimimmetics: 
They  allosterically  regulate  calcium  sensing  receptor  and  by  
sensitizing  parathyroid  calcium  receptor  to  extracellular  calcium  inhibit  
PTH  secretion. Cinacalcet  is  the  only  agent  available  in  this  class.  It  is  
used  as  an  add  on  therapy  to  usual  treatment (active  vitamin D or  
phosphate  binders)   to  reduce  calcium  and  phosphate  levels. It  lowers  
phosphate  levels  by  causing  PTH  reduction, reduced  phosphate  
translocation  from  bone  but  has  no  effect on  intestinal  phosphate  
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reabsorption (differs  from  vitamin D). it  is  used  only  in  stage  5  CKD  and  
not  recommended  before  due  to  hypocalcemia  and  paradoxical  increase  in  
serum  phosphate  levels  and  for  phosphate  binders.  
Adynamic  bone  disease: 
Limiting  calcium  load  and  active  vitamin  D  treatment  are  the  best  
measures  to  prevent  and  treat  ABD. Calcium  is  the  most  potent  
suppressor  of  PTH  release. Patients  treated  with  calcium  containing  
phosphate  binders  exhibit  high  rates  of  ABD. Sevelamer  and  lanthanum  
are  preferable  phosphate  binders  in  high  risk  patients.  Exposure  to  high  
calcium  dialysate  also  suppress  PTH.  Thus  ABD  is  common  in  patients  
undergoing  peritoneal  dialysis  than  hemodialysis.  Low  doses  of  active  
vitamin D  is  beneficial  because  excessive  dose  can  cause  greater  reduction 
in  PTH
43
. 
F. Intervention  for  minimizing  cardiovascular  diseases: 
Control  of  hyperlipidemia: 
The  common  abnormalities  seen  in  CKD  are  hypertriglyceridemia  
and  elevated  LDL  levels. Current  guidelines  recommend  statin  therapy  for  
all  patients  as  they  reduce  the  risk  of  cardiovascular  events  and  prevent  
accelerated  loss  of  renal  function. The  target  goal  is to  keep  LDL < 
100mg/dl  and  triglyceride < 180 mg/dl
60
.  Statins  reduce  total  cholesterol, 
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LDL, apo B and  TG  effectively. Effect  on  HDL  is  variable. They  also  
cause  dose  dependent  inhibition  of  receptor  mediated  endocytosis  of  
protein  in  proximal  tubular  cells  and  thus  exhibit  antiproteinuric  effects. 
Lp (a)  levels  are  not  reduced.  But  combination  therapy  of  nicotinic  acid  
derivative  and  statins  reduce  Lp (a)  levels
65
.  
Antiplatelet  therapy: 
Aspirin  at  low  dose  75 – 150 mg/day inhibits  production  of  TXA2 
(inducer  of  platelet  aggregation) by  acetylating  serine  residue  near  the  
active  site  of  platelet  COX1. Since  platelets  do  not  synthesize  new  
proteins  aspirin  inhibition  on  platelets  are  permanent. Thus  it  blocks  
platelet  aggregation. Aspirin  thus  reduces  risk  of  cardiovascular  events  in  
high  risk  patients  like  CKD. Even  at   this  low  dose  it  can  cause  serious  
GI  bleeds  in  these  patients. Hence  clopidogrel  is  used  which  is  an  
irreversible   ADP  receptor  antagonist  and  associated  with  less  bleeding  
incidence
24
. 
Blood  pressure  control: 
All  5  category  of  drugs (ACEI, ARBs, CCB, Beta blockers, thiazides)  
produced  significant  reduction  in  blood  pressure  from  pretreatment  values. 
For  each  initial  blood  pressure  10 mmHg  higher  the  reduction  was  
1mmHg (systolic  BP )  and  1.1 mmHg (diastolic  BP)  greater.  Also  the  
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effects  were  additive. They  are  similarly  effective  in  preventing  CHD  
events  and  strokes  but  CCB  had  a  greater  preventive  effect  on  strokes
61
.    
Treatment  of  CHF  and  IHD:   
Loop  diuretics  are  the  main   stay  of  treatment  for  achieving  and  
maintaining  euvolemia  in  cardiac  failure. ACEI  and  ARB  improve  
symptoms, morbidity  and  survival. ACEI  are  indicated  in  symptomatic  
heart  failure, asymptomatic  heart  failure  with  LVEF < 35%  and  in  post  MI  
patients  with  EF <40%. Beta  blockers  improve  prognosis  in  patients  with  
systolic  dysfunction. Due  to  association  of  risk,  digoxin  is  not  
recommended  as  first  line  therapy.   The  risks  are  toxicity  due  to  impaired  
clearance  and  arrhythmias  in  association  with  hypokalemia. Diastolic  
dysfunction  are  usually  treated  with  verapamil  or  diltiazem  as  they  
enhance  left  ventricular  diastolic  relaxation. 
CKD  patients  with  stable  angina  without  infarct  are  treated  with  
standard anti  anginal  drugs  for  symptomatic  relief. In  patients  with  infarct  
beta  blockers  and  ACEI  are  to  be  considered  as  they  reduce  mortality
81
. 
G. Nutritional  management: 
• Supplements – low  potassium  and  phosphate   with  high  calorie  
content 
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• Anti inflammatory  and  antioxidants  -  inflammation  and  oxidative  
stress are  associated  with  poor  outcomes  in  CKD. Statins  decrease  
CRP  levels  irrespective  of  lipid  levels. ACEI  exhibit  anti 
inflammatory  properties. Acetylcysteine  possesses  anti oxidant  
property  and  thereby  reduces  cardiovascular  adverse  events. 
Glitazones inhibit  activation  of  inflammatory  response  genes  and  
promote  immune  deviation  from  Th1  to  Th2  pathway.   
• Correction  of  anorexia – low  dose  megestrol  acetate  by  
downregulating  proinflammatory  cytokines  relieves  symptoms  of  
anorexia – cachexia  syndrome. Pentoxifylline  downregulates  
proinflammatory  cytokine  mediated  NOS  pathway,  inhibits  TNF α  
production  and  decreases  weight  loss  and  muscle  protein  wasting.  
Hence  used  in  MICS
45
.  
Step 4: Renal  replacement  therapy (RRT): 
Referral  to  nephrologist: 
Patients  with  CKD  should  be  referred  to  a  nephrologist  early  in  the  
course of   the  disease, before  the  plasma  creatinine  concentration  exceeds 
1.2  and 1.5 mg/dl  in  women  and  men   respectively  or  the  eGFR  is  less  
than  60ml/min/1.732m
2
.  Renoprotective  therapy  has  greatest  impact  if  
initiated  at  this  stage. 
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Indications: 
                RRT  includes  dialysis (peritoneal  dialysis  or  hemodialysis)  and  
renal  transplantation. The  main  indications  are 
• When  GFR  falls  to  10 ml/min/1.73m
2
  without  uremic  symptoms 
• Pericarditis  or  pleuritis 
• Progressive  uremic  encephalopathy  or  neuropathy  with  signs  such  as     
confusion,  asterixis,  myoclonus, wrist or foot  drop  or seizures  
• A  clinically  significant  bleeding  diathesis  attributable  to  uremia 
• Fluid  overload  refractory  to  diuretics 
• Hypertension  poorly  responsive  to  antihypertensive  medications 
• Persistent  metabolic  disturbances  that  are  refractory  to  medical  
therapy. These  include  hyperkalemia, metabolic acidosis, 
hypercalcemia, hypocalcemia, and  hyperphosphatemia.  
• Persistent  nausea  and  vomiting 
• Weight  loss  or  signs  of  malnutrition
31
 
Prognosis:  
The  five  year  survival  rate  on  dialysis  depends  on  underlying 
disease  which  is  36%  for  diabetic  kidney  disease, 53%  for   
glomerulonephritis.  But  the  overall  survival  rate  is  39%.  Life  expectancy  
of  patients  on  dialysis  is  3 – 5 yrs. The  most  common   cause  of  death  in  
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CKD  is  cardiac  diseases (> 50%). Other  causes  are  infection, CVA  and  
malignancy
42
.   
RECENT  ADVANCES  IN  MANAGEMENT  OF  CKD: 
L  and  T  type  calcium  channel  blockers: 
T  type  calcium  channels  are  found  in  both  afferent  and  efferent 
arteriole.  L/T  type  blockers  dilate  both  the  arteriole  and  attenuate  
glomerular   hypertension  and  reduce  proteinuria.  They  also  suppress  
mesangial  cell  proliferation  by  inhibiting  activator  protein – 1. The  drugs  
in  this  class  are  benidipine, manidipine  and  efonidipine
82
.      
ETA (Endothelin A) Antagonism:  
ET-1  acts  on  the  ETA  located  in  vascular  smooth muscle  cells, 
myocardium,  fibroblasts,  kidney and  platelet . The ETA receptor  stimulation  
produces  vasoconstriction, fluid retention, proliferative effects, cardiac  
hypertrophy  and  releases  norepinephrine  and  Ang II . ETA  receptor  
stimulation  also  stimulates  the  release  of  cytokines  and  growth  factor  and  
facilitates  platelet aggregation. Endothelin  receptor  A  antagonist  has  been  
shown  to  reduce  systolic  and  diastolic  BP  and  to  offer  renoprotection
83
.  
Bone  Morphogenetic  Protein – 7 (BMP – 7): 
It  is  an  endogenous  antagonist  of  TGF β  and  thereby  inhibits 
epithelial  to  mesenchymal  transition  involved  in  interstitial  fibrosis. 
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Pirfenidone:  
It  is  an  orally  active  antifibrotic  agent  that  confers  renoprotection  
in  CKD
61
. 
ACE – 2:  
It  facilitates  degradation  of  angiotensin  II  to  angiotensin (1-7)  which  
is  a  vasodilatory  and  antiproliferative  mediator. So  recombinant  ACE 2  is  
tried  for  renoprotection
39
. 
CERA (Continuous  Erythropoiesis Receptor Activator):  
It  is  synthesized  by  integration  of  epoetin  beta  with  30 kDa  
methoxy  polyethylene  glycol  polymer. It  has  a  very  long  t1/2  of  130 hrs  
and  hence  administered  every  2-4 weeks. 
Peginesatide:  
It  is  a  pegylated  synthetic  dimeric  peptide  that activates  EPO – R  
but  bears  no  sequence  homology  with  endogenous  erythropoietin  and  
hence  it  is  unrecognizable  by  anti EPO antibodies. T1/2  is  14-60 hrs  and  
given  as  monthly  dosing. 
HIF  Prolyl  Hydroxylase  Inhibitors  (PHI):  
It   is  orally  active  oxoglutarate  analogs  that  inhibits  prolyl  
hydroxylase  degradation  (PHD)  proteins  which  are  responsible  for  
hydroxylation, ubiquitination  and  degradation  of  Hypoxia  inducible  factor 
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α. Thus  it   leads  to  stabilisation  of  HIF α  and  thereby  promote  EPO  
release
37
.  
ARTICLES  RELATED  TO  AMLODIPINE: 
1. In  a  randomized  trial  conducted  by  Yasuhiko  et al  between  
losartan  and  amlodipine  for  12  months  in  patients  with  CKD  and  
hypertension,  both  the  drugs  exerted  the  same  efficacy  for  blood  pressure  
control; but  losartan  significantly  reduced  24hr  urinary  protein  excretion  at  
months  3, 6, 12(20.7%, 35.2%, 35.85%  reduction)  whereas  amlodipine  did  
not  change  the  amount  of  proteinuria  during  the  study  period
84
. 
2. In  another  randomized  trial  by  Praga  M  et  al  between  losartan  
and  amlodipine  conducted  in  patients  with  non  diabetic  proteinuric  renal  
diseases, proteinuria  decreased  by  32.4%  after  4  weeks  of  treatment  and  
by  50.4%  after  20  weeks  of  treatment  in  losartan  group  whereas  no  
significant  proteinuria  changes  were  observed  in  amlodipine  group. Also  
target  blood  pressure  was  achieved  with  initial  dose  of  study  medication  
in  76%  in  losartan  group (50mg  daily)  and  68%  in  amlodipine  group  
(5mg  daily)
85
. 
3. A  randomized trial  by  Abe  et  al  between  amlodipine  and  
benidipine  in  patients  with  stage  3 – 5  CKD  as  add  on  therapy  to  ARBs  
showed  that  there  were  no  differences  between  systolic BP(A – 
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133.4±1.3mmHg , B – 136.1±1.8mmHg)  and  diastolic  BP(A – 75.2±1.6, B – 
78.6±1.7)  at  the  end  of  6 months. Heart  rate  did  not  differ  between  the  
groups (A – 74.6± 2.3, B – 76.1±2.2). Serum  creatinine  increased  and  eGFR  
decreased  significantly  in  both  the  groups. Urine  PCR was  significantly  
lower  in B group  than  in  A group (B – 2565±299.9 vs A – 3178±372.2 mg/g 
Cr , p<0.05)  at  6  months
86
. 
4.  A  prospective  study conducted  by  Agodoa  et  al  between  ramipril  
and  amlodipine  in  patients  with  hypertensive  nephrosclerosis  showed  that  
the  mean  decline  in  GFR  was  2.07  and  3.22  ml/min/1.73m
2
  per  year  in  
ramipril  and  amlodipine  group  respectively. Thus  the  mean  decline  was  
1.15 ml/min/1.73m
2
 per  year  or  36%  slower  in  ramipril  group. Proteinuria  
increased  by  58%  from  0.0997  to  0.1575  in  amlodipine  group  and  
declined  by  20%  from  0.1147  to  0.0915  in  ramipril  group.   The  risk  
reduction  for  ramipril  vs  amlodipine  groups  in  the clinical  end  points 
(ESRD, death, 50% decline  in  GFR)  was  38%
87
. 
5. In  a  randomized  trial  by  Tanaka  et  al  between  nifedipine  CR  
and  amlodipine  as  add  on  therapy  to  valsartan  in  CKD  patients  showed  
that  urine  ACR  at  16  weeks  (23±24 mg/g Cr)  was  significantly  less  than  
that  at  0 weeks (49±63)  in  VN  group  but  not  in  VA  group (39±39  at 0 
weeks  and  50±95  at 16 weeks). Serum  creatinine  was  significantly  greater  
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at  16  weeks(1.03±0.34mg/dl) in  VA  group  compared  to  0 
weeks(0.92±0.27)  but  not  in  VN  group (0 weeks – 0.9±0.1  and  16 weeks – 
0.9±0.2)
88
. 
ARTICLES  RELATED  TO  CILNIDIPINE: 
1. In  a  prospective  study  conducted  by  Nakatsu  et  al  in  
asymptomatic  non – diabetic  hypertensive  patients  who  received  cilnidipine  
monotherapy  showed  that  mean  ± SD  for  morning  systolic  BP  and  urine  
albumin creatinine  ratio  decreased  by  20.4 ± 11.4mmHg  and  15.2±13.1mg/g  
creatinine  respectively.  The  time  constant  for  UACR  reduction  was  
significantly  longer  than  that  for  BP  reduction (43.5±22.9 vs 15.4±7.1 
days)
89
. 
2. In  a  study  conducted  by  Kanaoka, Tamura  et  al  with  cilnidipine  
as  add  on  therapy  to  renin  angiotensin  inhibitors  for  24  weeks  showed  
that  left  ventricular  mass  index  was  significantly  decreased  in  cilnidipine  
group  compared  to  control  group (change  in  LVMI  -12.4±23.7 vs 
26.2±64.4; p=0.007). Also  24  hr  and  daytime  systolic  BP  (from  
ambulatory  BP  monitoring) were  significantly  lower  in  cilnidipine  group  
compared  to  control  CCBs
90
. 
3. In  a  study  where  diabetic  patients  on  other  CCBs  were  switched  
over  to  cilnidipine, it  was  found  that  after  substitution  BP  did  not  
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significantly  change, but  heart  rate  decreased  from  73.9±7.1 beats/min  to  
72±8.4 beats/min  and  the  log  transformed  UACR  decreased  to  82.9±49.4%  
of  baseline  values
91
. 
4. In  a  comparative  study  between  valsartan  and  valsartan  plus  
cilnidipine  in  diabetic  patients  for  1  year  it  was  found  that  UACR  was  
markedly  decreased  in  combination  therapy  group  rather  than  
monotherapy  group (reduction rate 44±11% vs 9±7%)
92
. 
5. A  prospective  study  between  cilnidipine  and  benazepril  showed  
that  urine  albumin  excretion  significantly  decreased  in  both  the  groups  
with  no  significant  difference  between  the  groups. The  levels  of  serum  
creatinine were unchanged  throughout  the  study  in  both  the  groups
93
.   
AMLODIPINE  VERSUS  CILNIDIPINE:   
1. In  a  study  by  Abe  et  al  conducted  in  CKD  patients  who  
received  either  cilnidipine  or  amlodipine  for  48  weeks, a  significant  and  
comparable  reduction  in  systolic  and  diastolic  BP  was  observed  in  both  
the  groups. The  percent  reduction  in  urinary  ACR  and  Liver  type  fatty  
acid  binding  protein (L – FABP)  was  significantly  greater  in  cilnidipine  
group  than  amlodipine  group. Plasma  renin  activity  did  not  differ  between  
the  groups  but  plasma  aldosterone  levels  was  significantly  decreased  in  
cilnidipine  group
94
. 
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2.  In  a  comparative  study  between  amlodipine  and  cilnidipine  for  
12  months  in  renal  disease  patients , amlodipine  showed  significant  
increase  in  proteinuria (87% increase of  baseline  values)  while  the  increase  
was  suppressed  in  cilnidipine  group(4%  increase  of  baseline  values). Also  
cilnidipine  showed  an  increase  in  creatinine  values (baseline vs 12 months 
1.36±0.20 vs 1.5±0.23 mg/dl)
95
. 
3. In  SAKURA  trial  conducted  between  L/N  type  and  L  type  
calcium  channel  blockers  for  12  months  showed  that  both  the  drugs  
equally  decreased  the  BP. UACR  for  cilnidipine  and  amlodipine  before  
treatment   (111.5±138.97  and  88.29±63.45 mg/g)  and  after  treatment 
(107.93±130.23  and  89.07±97.55)  did  not  differ  much. Thus  there  was  
similar  changes  in  UACR, serum  creatinine  and eGFR. Cilnidipine  effects  
were  similar  to amlodipine  and  did  not  offer  additional  benefit
96
. 
4. In  a  cross  over  study  among  4  types  calcium  channel  blockers  in  
CKD  patients  showed  that  BP  reduction  was  comparable  among  them. 
Baseline  urinary  albumin  excretion  was 69.4. UAE  endpoints  seen  with  the  
drugs  were nifedipine CR  30.8, cilnidipine 33.9, efonidipine 51  and  
amlodipine 40.6. Angiotensin  II  was  significantly  lower  in  cilnidipine  than  
amlodipine. Plasma  aldosterone  concentration  was  significantly  lower  in  
cilnidipine  and  efonidipine  as  compared  to  amlodipine
97
.   
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Thus  in  many  clinical  studies  it  was  found  that  cilnidipine  had  
superior  antiproteinuric  effects  and  found  to  be  more  efficacious  than  
amlodipine  in  renal  diseases. It  was  also  found  that  combination  therapy  
of  RAS  inhibitors  and  CCBs  were  more  effective  in  reducing  proteinuria  
and   BP  levels  than  monotherapy  with  either  of  the  drugs  in  CKD  
patients. With  the  above  extensive  literature  review,  this  study  was  
designed  to  compare  the  efficacy  and  tolerability  of  cilnidipine  and  
amlodipine  and  to  prove  the  advantages  of  cilnidipine  over  amlodipine  as  
add  on  therapy  to  ARB (Losartan)  in  CKD  patients.                     
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AIM   OF  THE  STUDY 
                       To  compare  the  efficacy  and  safety  of  cilnidipine  and  
amlodipine   as  add  on  therapy  in  chronic  kidney  disease  patients  who  are  
on  losartan  for  > 2  months.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
79 
 
METHODOLOGY 
STUDY  TYPE: 
Interventional  clinical  study 
STUDY  DESIGN: 
Open  label, randomized, prospective, comparative, parallel  group  
study. 
STUDY  PERIOD:  
April 2013 – May 2014 
STUDY  CENTRE: 
It  is  a  single  centered  study  conducted  in  the  out  patient  
Department  of  Nephrology, Tirunelveli  Medical  College, Tirunelveli   
SAMPLE  SIZE: 
100  (50  patients  in  cilnidipine  group  and  50  patients  in  amlodipine  
group). 
ETHICAL  CONSIDERATIONS: 
This  study  was  approved  by  Instituitional  Ethical  Committee  of  
Tirunelveli  medical  college  Hospital.  Written  informed  consent  was  
obtained  in  local  vernacular  language  from  every  patient  before  
enrollment.   
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INCLUSION  CRITERIA: 
 Patients  of  both  sex   
 Patients  aged  > 18  years  and  < 80  years 
  Patients  diagnosed  as  having  CKD  with  type  II  diabetes  mellitus  
with  GFR  < 90 ml/min/1.73m
2
 
 
 
Patients  should  be  on  losartan  50 mg once  daily  for  > 2  months  
before  administration  of  cilnidipine  or  amlodipine 
 Patients  with  systolic  BP  ≥130  and < 180 mmHg  and  diastolic  BP  ≥ 
80  and < 110 mmHg 
 Patients  with   urine  protein  creatinine  ratio  < 0.2 g/g creatinine 
(normal protein excretion ) or  ≥ 0.2 g/g creatinine  (clinical proteinuria). 
EXCLUSION  CRITERIA: 
 Patients less  ≤ 18 or ≥ 80  years  of  age  
 Hypertensive  emergency ( systolic  BP ≥ 180 mmHg ;  diastolic  BP ≥ 
110 mmHg.) 
 Patients  not  taking  losartan 
 Earlier  treatment  with  steroids  or  immunosuppressants 
 Renovascular  hypertension 
 Patients  on  renal  replacement  therapy (dialysis  and  transplant  
recipient  patients) 
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 Patients  with  uncontrolled  diabetes  mellitus  or  complications  of  
diabetes  such  as  DKA  that  required  hospitalization  
  Patients  with  the  history  of    hypersensitivity  to  calcium  channel   
blockers 
 Patients  with  severe  heart  failure , arrythmia, angina  and  myocardial  
infarction  within  6  months  before  starting  the  study 
 Patients  with  the  history  of  convulsions 
 Patients  with  stroke, hepatic  impairment  within  6  months  before  
starting  the  study. 
WITHDRAWAL  CRITERIA: 
 Blood  pressure  ≥ 180/110 
 Noncompliance  with  protocol 
 Protocol  deviation 
 Request  for  withdrawal  by  the  subject 
 Adverse  effects ( decision  about  withdrawal  from  the  study  was  
made  either  by  subject  or  investigator) 
SCHEDULE  OF  STUDY  VISIT: 
a) Screening  and  recruitment: 
                The  subjects  were  enrolled  based  on  inclusion  criteria  after  
screening.  During  enrollment  clinical  assessment  and  the  following  
baseline  investigations  were  done.  
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• Blood  sugar, serum  creatinine, potassium  and  hematocrit  were  done  
in  a  random  blood  sample  using  automated analyser. 
• Estimated  glomerular  filtration  rate  was  calculated  by   Modification  
of  diet  in  renal  disease (MDRD)  study  equation  as  follows 
Estimated GFR = 1.86 x ( Pcr )
-1.154
 x ( age )
-0.203 
(Multiply  by  0.742  for  women) 
• Spot  urine  protein  creatinine  ratio  (the  ratio  of  spot  urine  protein  to  
creatinine  expressed  as  g/g cr )  was  measured  by  automated  assay. 
The  urine  samples  were  collected  at  anytime  in  the  morning. Values  
represents  the  mean  of  2  measurements  done  in  1  week  period.    
          Urine  PCR < 0.2 – NORMAL 
          Urine  PCR ≥ 0.2 – CLINICAL PROTEINURIA  
• Blood  pressure  was  measured  manually   after  5  minutes  of  rest  
twice  atleast  2  mins  apart  in  right  arm  in  sitting  posture  with  the  
cuff  at  heart  level  using  sphygmomanometer. 
• Pulse   rate  was  assessed  by  palpating  the  radial  artery  on  radial  
side  of  the  wrist  with  tips  of  index , middle  and  ring  fingers  after  
5 minutes  of  rest. 
• Categorizing  the  stages  of  CKD  based  on  GFR  levels 
Stage 1 = ≥ 90 ml/min/1.73m
2
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Stage 2 = 89 – 60 ml/min/1.73m
2
 
Stage 3 = 59 – 30 ml/min/1.73m
2
 
Stage 4 = 29 – 15 ml/min/1.73m
2
 
     Stage 5 = < 15 ml/min/1.73m
2 
b) Randomisation: 
After  enrollment  subjects  were  randomized  into  2  groups (group 1  
and  group 2)  with  the  help  of  computer  generated  random  table.  
c) Treatment  protocol:  
The  patients  received  the  drugs  as  follows 
Group 1: T. Cilnidipine  10 – 20 mg/day for  6 months 
Group 2: T. Amlodipine  5 – 10 mg/day  for  6 months.  
After  randomization  group 1  patients  were  started  on T.Cilnidipine  
10 mg  once  daily   and  group  2    patients  were  given  T. Amlodipine  5 mg  
once  daily  initially. The   patients  were  reviewed every 2  weeks.  If  the  
magnitude  of  reduction  in  blood  pressure  was  insufficient (systolic  BP < 
20mm Hg  and  diastolic  BP < 10mm Hg)  the  dosage  was  increased  to  
10mg  twice  daily  and  5mg  twice  daily   for  cilnidipine  and  amlodipine  
respectively. Both  the  drugs  were  given  orally  either  once  or  twice  daily  
for  a  duration  of  6  months  for  each  patient. Also  the  patients  were  given  
a  diary  to  note  down  the  adverse  events. The  tablets  were  provided  for  
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15  days  only. Then  the  patients  were  instructed  to  report  to  the  out  
patient  department  after  2  weeks  along  with  the  diary  and  empty  strips  
to  collect  the  drugs.  During  this  visit  blood  pressure  was  monitored, 
compliance  was  assessed  by  pill count  method  and  adverse  effects  if  any  
were  recorded. Cilnidipine Tablets (Cilacar) 10mg were donated by 
J.B.Chemicals and Pharmaceuticals. 
C) Follow  up  : 
At  the  end  of  1
st
 , 3
rd
  and  6
th
  month, clinical  examination  including  
vital  signs such  as  blood  pressure, pulse  rate  and  laboratory  investigations  
such  as blood  sugar, serum creatinine, potassium, spot  urine  protein  
creatinine  ratio  were  performed.  Also  estimated  GFR  was  calculated  and  
categorization  of  stages  of  CKD  based  on  GFR  was  done. 
EFFICACY  PARAMETERS: 
PRIMARY  ENDPOINT: 
• Changes  in  spot  urine  protein  creatinine  ratio  from  the   baseline  to  
the  endpoint (at  the  end  of  6 months). 
SECONDARY  ENDPOINT: 
• Changes  in  blood  pressure  from  the  baseline  to  the  endpoint 
• Changes  in  serum  creatinine  from  the  baseline  to  the  endpoint 
• Changes  in  estimated  GFR  from  the  baseline  to  the  endpoint 
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• Changes  in  pulse  rate  from  the  baseline  to  the  endpoint 
• Progression/Regression  of  CKD  stages 
STATISTICAL  ANALYSIS: 
1. The  baseline  characteristics  of  both  the  groups  were  expressed  as  
descriptive  statistics (mean, standard  deviation).  They  were  matched  by  
unpaired  student  ‘t’  test  and  Pearson’s  chi-square  test. 
2. For  analysis  and  interpretation  of  variables  within  the  group,  student  
paired ‘t’  test  and  wilcoxon  signed  rank  test  were  used  for  normal  and  
non normal  data  respectively. 
3. For  analysis  of  variables  between  the  groups,   unpaired ‘t’  test  and  
mann whitney  u  test  were  carried  out  for  normal  and  non  normal  data  
respectively. 
4. The  categorical  variables  between  the  two  groups  were  compared  by  
chi  square  test  of  proportions. 
5. Adverse  events  were  expressed  as  percentages.   
                    The  above  statistical  analysis  was  done  with  the  help  of  
statistical  package  namely  IBM  SPSS  Statistics  11  by  adopting  the  
following  test  of  significance. The  p  value  less  than  0.05   was  considered  
as  significant  in  two  tailed  conditions.   
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PATIENT  DISPOSITION: CONSORT  DIAGRAM 
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T.Cilnidipine n=50 
 
 
    
 
 
 
 
Completed study n=46 
 
 
Patients screened 
 
T. Amlodipine n=50 
             4  withdrawn 
1 – adverse event 
2 – BP ≥ 180/110 
    1 – Non compliance 
 
Completed  study n=50 
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RESULTS 
               In  the  period  of  1 year  from  April  2013  to  May  2014, 100  
cases  of  diabetic  chronic  kidney  disease  attending  the  outpatient   
Department  of  Nephrology  with  eligibility  criteria  were  included  in  the  
study. The  patients  were  then  randomly  assigned  into  2  groups  receiving  
either  T. Cilnidipine   or  T. Amlodipine . 4  patients  in  cilnidipine  group  
were  withdrawn (1 patient  due  to  adverse  event; 2  patients  due  to  blood  
pressure  elevation; 1 patient  due  to  non  compliance). In  amlodipine  group  
no  one  was  withdrawn. Totally  96  patients  completed  the  study  and  the  
results  were  statistically  analysed. 
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TABLE 1: BASELINE  CHARACTERISTICS 
Baseline 
parameters 
Cilnidipine 
(mean) 
(n – 46 ) 
Amlodipine 
(mean) 
(n – 50) 
p value 
Age (SD) 
 
59.19 (8.10) 55.16 (8.50) 0.019
 
Sex 
 
Male 
 
33 33  
0.544 
Female 
 
13 17 
Urine PCR 
 
1.94 1.38 0.014
 
Serum creatinine 
 
3.13 2.75 0.158 
eGFR 
 
25.28 29.6 0.142 
Systolic BP 
 
149.13 148.40 0.779 
Diastolic BP 
 
92.17 90.8 0.461 
      Pulse rate 
 
79.7 78.82 0.525 
 
               Table  1: summarizes  the  baseline  characteristics  of  patients  
enrolled  in  the  study. There  were  no  statistical  difference in  the  baseline  
parameters  between  cilnidipine  and  amlodipine  group  except  for  age (p - 
0.01) and  urine  protein  creatinine  ratio  which  was  high  in  cilnidipine  
group (p - 0.014). 
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TABLE 2 
CHANGES   IN   MEAN  PARAMETERS   FROM  BASELINE  AT  
THE  END  OF  1
ST
, 3
RD
 AND  6
TH
 MONTH   IN  CILNIDIPINE  GROUP 
 
 
Parameter 
 
Baseline  
(mean± 
    SD) 
 
 1 month 
(mean± 
     SD) 
 
P value 
 
 
 
3 months 
(mean± 
SD) 
 
P 
Value 
 
6 months 
(mean± 
     SD) 
 
P 
Value 
 
n 46 46  46  46  
 
Urine PCR 
(g/g cr) 
 
1.94±1.22 
 
 
1.43±0.92 
 
< 0.001
* 
 
1.12±0.75 
 
 
< 0.001
* 
 
1.09±0.72 
 
 
< 0.001
* 
 
Serum 
creatinine 
(mg/dl) 
 
3.13±1.34 
 
 
3.16±1.55 
 
0.73 
 
3.22±1.46 
 
 
0.22 
 
3.25±1.44 
 
 
0.045
* 
 
eGFR 
(ml/min/1.73
m2) 
 
25.2±14.2 
 
26±14.3 
 
0.68 
 
24.6±13.3 
 
 
0.41 
 
24.4±13.1 
 
 
0.28 
 
 
Systolic 
BP 
(mmHg) 
 
149.13± 
12.7 
 
127.6± 
14.3 
 
< 0.001
*
 
 
126.52± 
13.6 
 
< 0.001
*
 
 
126.73± 
12.1 
 
< 0.001
*
 
 
Diastolic 
BP  
(mmHg) 
 
92.17±8.4 
 
80.65± 
10.2 
 
< 0.001
*
 
 
78.91±11 
 
< 0.001
*
 
 
79.35±7.7 
 
< 0.001
*
 
 
*p value < 0.05 statistically  significant 
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• Table 2  : shows  changes  in  mean  parameters  from  baseline  at  the  
end  of  1, 3  and  6  months  in  cilnidipine  group .The   results   are  
expressed  as  mean ± SD. 
• Change  in  UPCR  from  baseline  was  significantly  lower  in  
cilnidipine  group  at  the  end  of  1
st
  month  itself. Thereafter  PCR  
progressively  regressed   throughout  the  study  period  (p<0.001). 
• The  increase  in  creatinine  levels  did  not  change  statistically  at  the  
end  of   3 months  ( baseline vs 3 months: 3.13±1.34 vs 3.22±1.46; 
p=0.22)  but  it  was  statistically  significant  at  the  end  of  6 months  
(3.13±1.34 vs 3.25±1.44; p=0.04). 
• Estimated  GFR  increased  at  the  end  of  1
st
  month of  treatment.  
Thereafter  GFR  decreased  gradually. Both  the  increase  and  decrease  
in  eGFR  from  baseline  was  statistically  insignificant.  ( p = 0.68 ; p = 
0.41; p = 0.28). 
• Both  systolic  and  diastolic  BP  decreased  significantly  from  baseline 
at  the  end  of  1, 3  and  6  months (p<0.001). 
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TABLE 3 
CHANGES   IN   MEAN   PARAMETERS  FROM  BASELINE  AT  
THE  END  OF  1
ST
, 3
RD
  AND  6
TH
  MONTH  IN  AMLODIPINE  
GROUP 
 
Parameter 
 
Baseline  
(mean± 
SD) 
 
 1 month 
(mean± 
    SD) 
 
P value 
 
 
 
3 months 
(mean± 
SD) 
 
P 
Value 
 
6 months 
(mean± 
SD) 
 
P 
Value 
 
N 50 50  50  50  
 
Urine PCR 
(g/g cr) 
 
1.38±0.98 
 
 
1.41±0.83 
 
0.47 
 
1.30±0.71 
 
 
0.83 
 
1.40±0.65 
 
 
0.21 
 
Serum 
creatinine 
(mg/dl) 
 
2.75±1.28 
 
 
2.83±1.33 
 
0.76 
 
2.84±1.25 
 
 
0.15 
 
2.87±1.28 
 
 
0.02
* 
 
eGFR 
(ml/min/1.73
m2) 
 
29.6±14.9 
 
28.9±14.6 
 
0.84 
 
27.8±14 
 
 
0.1 
 
27.6±13.9 
 
 
0.1 
 
 
Systolic 
BP 
(mmHg) 
 
148.4± 
12.67 
 
125.2± 
13.5 
 
< 0.001
*
 
 
124.8± 
11.1 
 
< 0.001
*
 
 
122.6± 
14.5 
 
< 0.001
*
 
 
Diastolic 
BP  
(mmHg) 
 
90.8±9.6 
 
76.4±9.8 
 
< 0.001
*
 
 
78±7.8 
 
< 0.001
*
 
 
77.4±7.7 
 
< 0.001
*
 
 
*p value < 0.05 statistically  significant 
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• Table  3: shows  changes  in  mean  parameters  from  baseline  at  the  
end  of  1 , 3  and  6  months  in  amlodipine  group. The  results   are  
expressed  as  mean ± SD. 
• In  amlodipine  group  there  was  no  change  in  urinary  PCR  from  
baseline  at  the  end  of  1, 3  and  6 months  statistically.  (p=0.47; 
p=0.83; p=0.21). 
•  The  mean  serum  creatinine  concentration  increased  gradually  and  
attained  statistical  significance  at  the  end  of  6  months (baseline vs 6 
months: 2.75±1.28 vs 2.87±1.28; p=0.02). 
• The  estimated  GFR  decreased  progressively  but  it  was  statistically  
insignificant  with  respect  to  baseline  at  the  end  of  1, 3  and  6  
months  
( p = 0.84; p = 0.1; p = 0.1). 
• Both  systolic  and  diastolic  BP  decreased  significantly  from  baseline  
at  the  end  of  1, 3  and  6  months. (p<0.001).  
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TABLE 4 
COMPARISON   OF   ANTIPROTEINURIC  EFFECTS  OF  
CILNIDIPINE  AND  AMLODIPINE 
 
 
    
Duration 
 
 
       Groups  
 
     
Mean 
difference of 
UPCR from 
baseline 
 
 
        
SD 
  
 
        P  value 
 
1 month 
Group 1 -0.50 0.63 
 
 
< 0.001
* 
Group 2 0.03 0.46 
 
3 month 
Group 1 -0.83 0.88  
< 0.001
* 
Group 2 -0.08 0.56 
 
 
6 month 
Group 1 -0.87 0.66 
 
 
         < 0.001
*
 
Group 2 0.01 0.6 
 
*p value < 0.05 statistically  significant 
• Table 4 : The  mean  difference  of  urine  protein  creatinine  ratio  from  
baseline  at  the  end  of  1, 3  and  6  months  in  both  the  groups  were  
analysed  and  interpreted  in  the  above  table. The  results  are  
expressed  as  mean  difference ± SD. 
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• In  cilnidipine  group  urinary  PCR  decreased  steadily  from  baseline  
during  the  study  period. Amlodipine   group  showed  a  decrease  at  
the  end  of  3  months  but  the  decrease  was  not  sustained  thereafter. 
At  the  end  of  6  months,  in  amlodipine  group  urine  PCR  returned  
to  baseline  values. Thus  after  6  months  of  treatment  urine  protein  
creatinine  ratio  had  decreased  in  cilnidipine  group  but  not  in  
amlodipine  group.  (-0.87±0.66 vs 0.01±0.6 ; p<0.001)  
Figure 1 
 
Figure.1: shows  the  pictorial  representation  of  changes  in  mean  urine  
protein  creatinine  ratio  at  the  end  of  1
st
, 3
rd
 and 6
th
 month  in  both  the  
groups. 
baseline 1m 3m 6m
cilnidipine 1.94 1.43 1.12 1.09
amlodipine 1.38 1.41 1.3 1.4
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TABLE 5 
PERCENTAGE  REDUCTION  OF  URINE  PCR IN  PATIENTS  WITH  
HIGH  GRADE  BASELINE  PROTEINURIA 
 
   
• Baseline   proteinuria  levels   were  categorized  into  2  groups 
  a) High  grade  proteinuria  – UPCR  ≥ 1.5 
            b) Low  grade  proteinuria   – UPCR  < 1.5 
• Changes  in  urine  protein  creatinine  ratio  from  baseline  with  respect  
to  the  above  groups  were  calculated  as  percentage  reduction  and  
analysed  at  the  end  of  3  and  6  months. 
• In  patients  with  high  grade  proteinuria, cilnidipine  group  showed  a  
 
reduction  of  45%  and  47%  of  urine  PCR  from  baseline  whereas  
amlodipine  group  showed  24%  and  20%  reduction  at  the  end  of  3  
and  6  months  respectively. The  percentage  reduction  was  high  in  
cilnidipine  group.   
• In  patients  with  low  grade  proteinuria, cilnidipine  group  showed  a   
Duration Cilnidipine     Amlodipine 
3 months 45% 24% 
6 months 46% 20% 
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decrease  in  urine  PCR  from  baseline  by  31%  and  41%   whereas  
amlodipine  increased  the  urine  PCR  by  17%  and  27%  at  the  end  
of  3  and  6  months  respectively. 
TABLE 6 
COMPARISON   OF   RENAL   FUNCTION   CHANGES   BETWEEN  
CILNIDIPINE   AND  AMLODIPINE   FROM  BASELINE 
 
 
 
 
Duration 
 
 
 
Group  
 
Serum creatinine 
 
Estimated GFR 
Mean 
difference 
from 
baseline 
    
SD 
 
P 
value 
     Mean 
Difference   
from 
baseline 
 
SD 
 
P 
value 
 
1 month 
Group 1 0.02    0.56  
0.59
 
0.72 7.73 
 
 
0.7
 
Group 2 0.07 0.35 -0.64 6.8 
 
3 month 
Group 1 0.08 0.47 
 
 
0.98
 
-0.61 5.82 
 
 
0.66
 
Group 2 0.09 0.43 -1.72 7.29 
 
 
6 month 
Group 1 0.12 0.39 
 
 
0.98
 
-0.87 7.01 
 
 
0.65
 
 Group 2 0.12 0.36 -1.92 6.71 
 
• Table 6: compares  the  renal  function  changes  from  baseline  in  both  
the  groups  at  the  end  of  1, 3  and  6  months. The  results  are  
expressed  as  mean  difference ± SD. 
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TABLE 7 
COMPARISON  OF  BLOOD  PRESSURE  CHANGES  BETWEEN  2  
GROUPS  FROM  BASELINE 
 
 
    
    
Duration 
 
 
       
Groups  
 
 
 
Systolic blood pressure 
 
 
 
Diastolic blood pressure 
Mean 
difference 
from 
baseline 
    SD P 
value 
Mean 
difference  
from 
baseline 
SD P 
value 
 
1 month 
Group 1 -21.5 9.88  
0.39 
-11.52 11.9  
0.27
 
Group 2 -23.2 9.57 -14.2 12.13 
 
3 month 
Group 1 -22.6 14.21  
0.69
 
-13.26 12.6  
0.84
 
Group 2 -23.6 10.25 -12.80 10.3 
 
 
6 month 
Group 1 -22.39 11.38  
0.21 
-12.82 10.6  
 0.79 
Group 2 -25.4 12.32 -13.40 10.4 
 
• Table 7: compares  the  blood  pressure  changes  at  the  end  of  1 , 3  
and  6   months  in  both  the  groups. The  results  are  expressed  as  
mean  difference ± SD. 
• The  difference  in  systolic  and  diastolic  BP  from  baseline  was     
insignificant    in  both  the  groups  at  the  end  of  1, 3  and  6  months.    
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Figure 3 
 
 
 
Figure  3: is  a  pictorial  representation  of  trends  in  systolic  and  diastolic  
blood  pressure  changes  in  both  the  groups. 
 
 
baseline 1m 3m 6m
cilnidipine 149.13 127.6 126.52 126.73
amlodipine 148.4 125.2 124.8 122.6
cilnidipine 92.17 80.65 78.91 79.34
amlodipine 90.8 76.4 78 77.4
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TABLE 8 
CHANGES  IN  CKD  STAGES  AT  THE  END  OF  6  MONTHS  IN  
THE  TWO  GROUPS 
                              
                   Progression  is  defined  as  worsening  by  one  stage  and  
regression  is  improvement  by  one  stage. The  CKD  stage  was  unchanged  
in  40 patients, advanced  in  3 patients  and  regressed  in  3  patients  after  
treatment  with  cilnidipine   and  was  unchanged  in  36 patients, advanced  in  
8  patients  and  regressed  in  6 patients  in  amlodipine  treated  group. Chi  
square  test  was  done   and  it  was  found  to  be  statistically insignificant 
(p=0.19). 
 
 
 
Study group 
Changes in CKD stages  
P value Unchanged Regression Progression 
GROUP 1 40 3 3  
0.19
 
 
GROUP 2 36 6 8 
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ADVERSE  EFFECTS: 
                    Both  the  drugs  were  well  tolerated. 1  patient  was  withdrawn  
from  cilnidipine  group  at  the  start  of  the  study  due  to  non  specific  chest  
pain  after  2  doses. ECG  was  normal  in  that  patient. Out  of  the  46  
patients  who  completed  the  study  in  cilnidipine  group, 6  patients  (13% )  
developed  adverse  effects. In  amlodipine  group  all  patients  completed  the  
study  and  no  one  was  withdrawn  due  to  adverse  event. 4  patients  (8%)  
out  of  50  in  amlodipine  group  developed   adverse  effects. All  these  
adverse  effects  were  mild  and  did  not  require  discontinuation  of  drugs. 
There  was  no  significant  differences  in  adverse  events  between  the  
groups. 
 
Adverse effects Cilnidipine Amlodipine 
Dizziness 1 2 
Peripheral edema 0 2 
Increased appetite 1 0 
Increased blood sugar 2 0 
Itching 1 0 
Gastritis 1 0 
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DISCUSSION 
Chronic  kidney  disease  is  a  major  risk  factor  for  cardiovascular  
disease. In hypertensive   patients   with  concomitant CKD, strict  
antihypertensive  therapy   is  recommended. Antihypertensive  therapy  are  
primarily  aimed  at  reducing  proteinuria  and  blood  pressure. The  first  line  
drugs  in  CKD  are  RAS  inhibitors   but  most  of  the  patients  require  
multiple  drugs  to  achieve  blood  pressure  targets. In  such  cases,  CCBs  are  
more  commonly  used  along  with  RAS  inhibitors  as  they  possess  potent  
hypotensive  effects
6
. Several  clinical  trials  have  also  suggested  that  
treatment  with  CCBs  and  ARB/ACEI  combination  was  more  effective  in  
preventing  cardiovascular  events. Hence  the  present  study  was  performed  
to  compare  the  combined  effects  of  cilnidipine  or  amlodipine   with   
losartan  in  patients  with  chronic  kidney  disease.  
Many  clinical  studies  have  demonstrated  that  proteinuria  is  an  
important  predictor  of  subsequent  progression  of  kidney  disease. 
Proteinuria  is  also  directly  associated  with  the  risk  of  development  of  
CAD. Thus reduction  in  proteinuria  protects  against  renal  and  
cardiovascular  failure. Recently, with  regard  to renal  and  cardiovascular  
outcomes  in  chronic  kidney  disease  patients,  antiproteinuric  
antihypertensive  drugs  are  considered  to  be  more  beneficial
98
.                   
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Proteinuria  was  assessed  by  urine  protein  creatinine  ratio  in  our 
study.  Random  spot  urine  samples  were  used  to  determine  UPCR. In  a  
study  conducted  by  Gai  et  al,  it  was  demonstrated  that urine  protein  
creatinine  ratio  in  spot  urine  sample  correlated  well  with  daily  urine  
protein  excretion
99
. Either  a  first  morning  or  a  random  spot  urine  sample  
can  be  obtained,  as  both  are  recommended  by Kidney  disease  outcomes 
quality  initiative  of  National  kidney  foundation
98
.  
In  our  study,  we  included  patients  with  clinically  proven  diabetic  
chronic  kidney  disease  on  treatment  with  losartan. Baseline  characteristics  
were  comparable  between  cilnidipine  and  amlodipine  group  except  for  
age (p - 0.01)  and  urine  protein  creatinine  ratio  which  was  high  in  
cilnidipine  group (p - 0.014). The  mean  age  of  the  patients  was  57.17  
years. Majority  of  the  patients  were  male  and  the  distribution  of  males  
and  females  were  similar  between  the  groups.   
In  the  analysis  of  primary  endpoint,  cilnidipine  treated  patients  
showed  a  steady  decrease  in  urine  protein  creatinine  ratio  whereas  in  
amlodipine  group  UPCR  decreased  at  the  end  of  3  months  but  returned  
to  baseline  at  the  end of  6  months. The  greater  antiproteinuric  effects  of  
cilnidipine  can  be  attributed  to   reduction  in  glomerular  pressure  caused  
by   vasodilation  of  efferent  arteriole   due  to  blockade  of  N – Type  
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calcium  channel. Amlodipine  being  a  predominant  L type  CCB,  does  not  
have  any  effect  on  efferent  arteriole  due  to  absence  of  L type  calcium  
channels  and  therefore  glomerular  pressure  is  not  reduced
98
. These  results  
were  consistent  with  several  other  studies  which  reported  that  cilnidipine  
exhibited  antiproteinuric  effect  greater  than  amlodipine
(6,95)
. 
In   patients   with   high  grade  baseline  proteinuria,   urine  PCR  was  
reduced  in  both  the  groups  after  3  and  6  months  whereas  in  patients  
with  low  level  proteinuria, cilnidipine  group  showed  a  reduction  but  in  
amlodipine  group  there  was  no  change  in  UPCR  levels. Thus  high  grade  
proteinuric  patients  responded  better  to  both  modalities  of  treatment. 
Based  on  antiproteinuric  effects,  it  was  found  that  cilnidipine  and  losartan  
had  an  excellent  additive  effects  at  all  ranges  of  proteinuria  whereas  
amlodipine  and  losartan  exhibited   additive  effects  only  in  patients  with  
urine  PCR   greater  than  or  equal  to  1.5 (urine  PCR ≥ 1.5).Thus  it  can  be  
translated  that  cilnidipine  may  reduce  cardiovascular  events  in  CKD  
patients  even  with  low  grade  proteinuria.   
On  analyzing  the  results  of  secondary  endpoints, the  serum  
creatinine  increased  in  both  the  groups  gradually.  The  difference  in   
increase  from  baseline  was  equal  in  both  the  groups (p=0.98). Estimated  
GFR  was  decreased  from  baseline  in  both  the  groups  but  the  decrease  
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was  not  statistically  significant. Both  cilnidipine  and  amlodipine  
maintained  the  renal  function  throughout  the  study  period. Thus  by  
maintaining  GFR  both  the  drugs  are  expected  to  improve  long  term  
prognosis  in  CKD  patients.   
Strict   BP  control  is  another  important  parameter  to  prevent  the  
progression  of  renal  disease. Lowering  of  BP  is  also  associated  with  
significant  fall  in  cardiovascular  event. Both  systolic  and  diastolic  BP  
decreased  significantly  from  baseline  in  both  the  groups  at  the  end  of  1, 
3  and  6  months. The  difference  in  blood  pressure  reduction  was  equal  in  
both  the  groups.  Subjects  with  BP  less  than  130/80  accounted  for  19%  
and  34%  in  cilnidipine  and  amlodipine  groups  respectively.   Thus  both  
the  drugs  were  equally  efficacious  in  decreasing  the  BP  and  maintaining  
the  reduction. But  the  percentage  of  patients  who  achieved  the  target  BP  
goal  was  high  in  amlodipine  group. As  systemic  blood  pressure  is  directly  
transmitted  to  glomerular  capillaries, amlodipine  by  causing  a  greater  
reduction  in  systemic  blood  pressure  is  expected  to  decrease  glomerular  
pressure  which  might  be  attributed  to  its  antiproteinuric  effects  seen  in  
some  patients  in  our  study.  
Many  studies  have  shown  that  higher  heart  rate  is  associated  with  
long  term  risk  of  cardiovascular  mortality  independent  of  other  risk  
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factors
100
.  In  our  study  pulse  rate  was  maintained  by  both  the  drugs. 
None  of  them  produced  reflex  tachycardia. This  result  was  similar  to  
CARTER  study  in  which  heart  rate  was  unaffected  by  both  the  drugs
98.
 
In  majority  of  patients,  CKD  stages  were  unaltered  by  both  the  
drugs. Nearly  6  patients (12%)  improved   in  amlodipine group. Worsening  
of  patients  was  less  in  cilnidipine  compared  to  amlodipine  group. But  all  
these  changes  were  statistically  insignificant. Thus  distribution  of  CKD  
stages   were  similar  between  the  two  groups  before  and  after  treatment 
(p=0.19).  
Both   the   drugs  were  well  tolerated. In  cilnidipine  group  1  patient   
developed  chest  pain  after  2  doses  and  was  withdrawn  from  the  study. 
ECG  was  normal  in  that  patient. Other  adverse  events  reported   were  mild  
and  did  not  require  discontinuation  of  the  drug. In  amlodipine  group , only  
a  few  adverse  events  were  reported  and  no  patients  were  withdrawn  due  
to  these  adverse  effects. No safety  concerns  were  raised  in  this  study. 
There   were   certain  limitations  in  our  study. First, since  baseline  
urinary  protein  excretion  showed  a  significant  difference  between  the  two  
groups  the  rate  of  change  in  urine  protein  creatinine  by  cilnidipine  might  
be  overestimated. Second, 24  hour  urine  collection  is  the  gold  standard  
test  for  assessment  of  urine  protein  excretion. But  it  might  be  difficult  for  
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the  outpatients  to  give  their  co – operation  and  hence  spot  urine  samples  
were  used. Though  spot  urine  sample  may  be  a  better  alternative  in  
clinical  practice, still  it  carries  some  limitations . Third, it  was an  open  
label  study  and  patients  were  followed  up  for  short  duration  only. Hence  
long  term  renoprotective  effects  were  not  determined. Fourth, relationship  
between  reduction  in  proteinuria  and  cardiovascular  events  were  not  
assessed.  
From  the  above  results  it  was  found  that  cilnidipine  was  equally  
efficacious  to  amlodipine  with  respect  to  blood  pressure  reduction  and  
maintanence  of  renal  function  but  based  on  antiproteinuric  effects  it  was  
found  to  be   more  beneficial  than  amlodipine  in  diabetic  chronic  kidney  
disease  patients  who  do  not  achieve  desired  treatment  targets  with  ARBs  
alone.  
 
 
 
 
 
 
 
108 
 
CONCLUSION 
In  conclusion,  cilnidipine  has  antihypertensive  effect  equivalent  to  
amlodipine  but  addition  of  cilnidipine  rather  than  amlodipine  to  losartan  
decreased  urine  protein  excretion   in  diabetic  chronic  kidney  disease  
patients. Therefore  combination therapy  with  cilnidipine  and  RAS  inhibitor  
may  be  more  beneficial  and  renoprotective  in  patients  with  diabetic  
chronic  kidney  disease. 
 
 
APPENDIX - I 
ABBREVIATIONS 
ADMA : Asymmetric  Dimethyl  Arginine 
ACEI  : Angiotensin  Converting  Enzyme  Inhibitor 
ARB  : Angiotensin  Receptor  Blocker 
ACE – 2   : Angiotensin  Converting  Enzyme 2 
ADH   :  Anti  Diuretic  Hormone 
ALP  : Alkaline  Phosphatase 
ABD  : Adynamic  Bone  Disease 
α SMA :  Alpha  Smooth  Muscle  Actin 
BNP    :         Brain  Natriuretic  Peptide 
BMP – 7 :     Bone  Morphogenetic  Protein  7 
CKD  :  Chronic  Kidney  Disease 
CRF  :    Chronic  Renal  Failure 
CAD  :    Coronary  Artery  Disease 
CVD   :   Cerebrovascular  Disease 
CVA  :    Cerebrovascular  Accident 
CHD   :    Coronary  Heart  Disease 
CHF  : Congestive  Heart  Failure 
CCB   :   Calcium  Channel  Blocker 
CERA :  Continuous  Erythropoiesis  Receptor  Activator 
CRP  :   C – Reactive  Protein 
CR  :  Continuous  Release 
COX  - 1   : Cyclo – Oxygenase – 1  
DKA   : Diabetic  Keto  Acidosis 
DRI   : Direct  Renin  Inhibitors 
eGFR   :   Estimated  Glomerular  Filtration  Rate 
ESRD  :  End  Stage  Renal  Disease 
EPO   : Erythropoietin 
EPOR  :   Erythropoietin  Receptor 
ET – A    :   Endothelin  A 
ET – B   :    Endothelin  B 
ESA   :   Erythropoiesis  Stimulating  Agents 
eNOS   :  Endothelial  Nitric  Oxide  Synthase 
ECM   :   Extracellular  Matrix 
ECFV    :   Extracellular  Fluid  Volume 
FGF – 23  :   Fibroblast  Growth  Factor 
GBM   :    Glomerular  Basement  Membrane 
GH    :   Growth  Hormone 
HIF α    :    Hypoxia  Inducible  Factor  Alpha 
HDL           :   High  Density  Lipoprotein 
IGF  :   Insulin  Like  Growth  Factor 
LVH  :  Left  Ventricular  Hypertrophy 
LVEF          :    Left  Ventricular  Ejection  Fraction 
LVMI :    Left  Ventricular  Mass  Index 
LDL  : Low  Density  Lipoprotein 
Lp(a)   :  Lipoprotein (a) 
LH   :   Leutenising  Hormone 
MS   :   Metabolic  Syndrome 
MICS  :   Malnutrition  Inflammation  Complex  Syndrome 
MGP  :   Matrix  Gla  Protein 
MDRD :   Modification  of  Diet  in  Renal  Disease 
MCP – 1 :    Monocyte  Chemoattractant  Protein 
NSAID   :   Non  Steroidal  Anti  Inflammatory  Drug 
PGE2   :    Prostaglandin  E2 
PCT  :    Proximal  Convoluted  Tubule 
PTH  :   Parathyroid  Hormone 
PTHR  :    Parathyroid  Hormone  Receptor 
PLMS :    Periodic  Limb  Movements  of  Sleep 
RAS   :   Renin  Angiotensin  System 
RAAS :   Renin  Angiotensin  Aldosterone  System 
rHuEPO  :  Recombinant  Human  Erythropoietin 
RRT  :   Renal  Replacement  Therapy 
TXA2 :   Thromboxane  A2 
TNF α :    Tumour  Necrosis  Factor  α 
TG   :    Triglycerides 
UPCR :   Urine  Protein  Creatinine  Ratio 
UAE   :   Urine  Albumin  Excretion 
UACR :   Urine  Albumin  Creatinine  Ratio 
VEGF   :    Vascular  Endothelial  Growth  Factor 
VDR  :    Vitamin  D  Receptor 
VLDL  :   Very  Low  Density  Lipoprotein 
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Study Title :  Comparison between anti proteinuric effects of cilnidipine & amlodipine as add on 
therapy in hypertensive patients with chronic kidney disease. 
StudyNumber__________________________________________________ 
Subject's Full Name _____________________________________ 
Date of Birth/Age_____________________________ 
Address 
______________________________________________________________________________
____________________________________________ 
 
1. I confirm that I have read and understood the information sheet dated for the above study 
and have had the opportunity to ask questions. or I have been explained the nature of the 
study by the Investigator and had the opportunity to ask questions 
2. I understand that my participation in the study is voluntary and that I am free to withdraw 
at anytime, without giving any reason and without my medical care or legal rights being 
affected. 
3. I understand that the sponsor of the clinical trial/project, others working on the Sponsor's 
behalf,the Ethics Committee and the regulatory authorities will not need my permission 
to look at my health records both in respect of the current study and any further research 
that may be conducted in relation to it, even if I withdraw from the trial. However, I 
understand that my Identity will not be revealed in any information released to third 
parties or published. 
4. I agree not to restrict the use of any data or results that arise from this study provided 
such a use isonly for scientific purpose(s) 
5. I agree to take part in the above study 
Signature (or Thumb impression) of the Subject/Legally Acceptable Representative: 
____________________ 
Signatory's Name ______________________________________  
Date __________________________ 
Signature of the Investigator _____________________________ 
Date __________________________ 
Study Investigator's Name ________________________________ 
Signature of the Witness ________________________________ Date 
__________________________ 
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1. ehd; NkNy Fwpg;gpl;Ls;s kUj;J Ma;tpd; tptuq;fis ehd; 
gbj;J Ghpe;J nfhz;Nld;. vd;Dila re;Njfq;fis Nfl;fTk;> 
mjw;fhd jFe;j tpsf;fq;fis ngwTk; tha;g;gspf;fg;gl;Ls;sJ 
vd mwpe;J nfhz;Nld;. 
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APPENDIX – III 
PROFORMA 
Group:                                                                        OP. NO: 
Random  Number: 
Patient’s  name:                                                          Date: 
Age/Sex:                                                                       
 Address:                                                                    Phone no: 
Diagnosis:                                                                      
Concomitant  medications: 
BP:                                                                             
PR: 
Investigations:     
                            Complete  blood  count 
                            Random  blood  sugar 
                            Blood  urea 
                            Serum  creatinine 
                            Serum  electrolytes 
                            Routine  urine  analysis 
                            Spot  urine  protein  creatinine  ratio 
 
 
ASSESSMENT 
 
 
PARAMETERS 
 
BASELINE 
 
1 MONTH 
 
3 MONTHS 
 
6 MONTHS 
 
Spot  urine  
protein  
creatinine  ratio 
 
    
 
Serum creatinine 
    
 
Estimated  GFR 
    
 
   CKD  stage 
 
    
 
Systolic blood 
pressure 
 
    
 
Diastolic  blood 
pressure 
 
    
 
Pulse  rate 
    
 
Dose  of  the  
drug 
    
 
ADVERSE  EFFECTS  (If  any): 
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